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1.0 Introduction: 
Oral cavity cancer is 12
th
 most common type of cancer related death worldwide (Parkin 
et al., 1999; Scully and Bedi, 2000). In 2008, Global Burden of Cancer (GLOBACAN) 
estimated the incidence of oral cancer (including lip cancer) as 263,900 cases and 
reported 128,000 of oral cancer related deaths (Jemal et al. 2011). In oral cancer, more 
than 90% is reported to be as epithelial neoplasia with majority of them is oral 
squamous cell carcinoma (OSCC) (Nagpal et al., 2003). OSCC is derived from the 
surface epithelium and then expanding upward from the basement membranes which 
replaces the normal epithelium. Since the basement membranes are usually being 
penetrated, the carcinoma will invadethe underlying connective tissue (Nagpal et al., 
2003; Silverman, 2003). In the present scenario, two-thirds of the new oral cancer cases 
are reported from the developing regions of the world (Parkin et al., 1999). These 
regions include parts of Africa, Central and South America, Caribbean, China, Asia, 
Melanesia and Micronesia/Polynesia (Parkin et al., 1999). Depending on the geographic 
locations, it has been noticed that there are variations in prevalence of oral cancers 
(Moore et al., 2000). However, reports suggest that these geographic variations are 
reflected mainly due to the prevalence of specific environmental and habitual influences 
rather than any genetically determined/ ethnic/ risk factors (Moore et al., 2000). 
Examples for these geographic variations in terms of their specific environmental or 
habitual conditions are; tobacco and alcohol consumption in Western and South Europe 
and also other Southern Africannations in relation to mouth and tongue cancer (Moore 
et al., 2000), betel quid chewing in Melanesia and South Central Asia (mainly India and 
Taiwan) in relation to cheek cancer (Werning and Mendenhall, 2007; Kao et al., 2009) 
and high recurrence of solar irritation in Australia and New Zealand in relation to lip 
cancer (Parkin et al., 1999; Parkin et al.,2005). Globally, OSCC is more frequent among 
males than in females with aratio of 2:1 (Parkin et al., 1999). Mostly, this male 
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preponderance is observed in the West (Moor et al., 2000), whereas in Malaysia, 
interestingly the female preponderance is reported (Ng et al., 1985; Siar et al., 1990). 
Despite the great therapeutic and diagnostic advancement in the past decade, the 
survival rate of oral cancer patient has not been improved much (Silverman, 2001).  
 
Carcinogenesis of oral cancer is a complex process which results from a multistep 
pathway involving the accumulation of genetic and chromosomal instability (Scully et 
al., 2000). This would lead to the activation of proto-oncogenes and inactivation of 
tumor suppressor genes (Choi and Myers, 2008). Considering the mere fact that huge 
numbers of genes are involved in oral carcinogenesis and tumor progression, as well as 
the cellular and molecular heterogeneity of OSCC, comprehensive studies are required 
to study the multiple gene alterations on a global scale (Estilo et al., 2009). 
 
There is an increasing demand over the incisional biopsy of the primary tumor to be 
used for refined initial characterization of the tumor. But, at present inciptional biopsy is 
used only for diagnosis of the disease and semi-quantitative estimate of malignancy by 
tumor grading (Bockmuhl et al., 2000). It becomes a necessity for the pathologist to 
answer whether or not the OSCC carries the potentiality for metastasis, if it is resistant 
to chemotherapy and/or radiotherapyand the prognosis of the patient (Bockmuhl et al., 
2000). Therefore, additional predictors and biomarkers are being extensively 
investigated with newer technologies with an aim for better patient management and for 
the provision of other treatment modalities such as radiotherapy and chemotherapy 
(Bockmuhl et al., 2000; Ludwig and Weinstein, 2005; Mishra and Verma, 2010).  
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The initial draft human genome sequencing was completed in 2001, where a total of 
30,000-35,000 genes were identified (International Human genome sequencing 
consortium, 2001). Further in 2003, a total of 24,500 coding genes have been estimated 
in the human genome by International Human Genome Sequencing Consortium (2004). 
This has prompted the use of molecular biology advancement to a whole new level. It 
has also initiated the development of high-throughput technologies like array-based 
comparative genomic hybridization (aCGH), which further enhanced the studies to 
screen entire genome in a single rapid assay (Marquis-Nicholson et al., 2010).  Indeed, 
high resolution array CGH is an important tool to discover genes that are involved with 
carcinogenesis and to filter out known alterations in the consensus (well known) regions 
(Davies et al., 2005). Infact, this tool (aCGH) has allowed researchers to focus on 
smaller areas in the genome (Davies et al., 2005). Apart from that, high resolution array 
CGH has increased the chances to detect small novel alterations as compared to lower 
resolution array CGH where small novel alteration may not be detected (Przybytkowski 
et al., 2011). This is because of the fact that when resolution is higher, the ability to 
discover genes associated with cancer are also increased (Davies et al., 2005). 
 
Oral squamous cell carcinoma (OSCC) is known to develop at various anatomical 
subsites within the oral cavity and therefore it forms heterogeneous tumor groups 
(Timar et al., 2005; Jarvinen et al., 2006). Due to its complexity, it has been suggested 
that different anatomical locations of tumor would portray different biological 
behaviour in terms of invasion and metastasis (Woolgar, 2005). Globally, OSCC of the 
cheek is more common in South East Asian countries, whereas tongue OSCC is 
common in Europe and other Western countries (Landis et al., 1998; Diaz et al., 2003; 
Sathyan et al., 2006). The biological difference between these 2 site of cancer might be 
due to variation in reflecting the association between risk habits practiced such as betel 
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quid chewing in India and South East Asia (Werning and Mendenhall, 2007), whereas 
tobacco and alcohol consumption in the West has been related to mouth and tongue 
cancers (MacFarlane et al., 1996; Paterson et al., 1996; Moore et al., 2000; Batsakis, 
2003; Parkin et al., 2005; Ridge et al., 2007).  In Malaysia, majority of the oral cancers 
are reported to be of tongue and cheek carcinomas (Lim et al., 2008). Both of these 
cancers are aggressive, but act differently. Tongue SCC is more aggressive and has the 
propensity to invade, leading to metastasis to the regional lymph nodes (Ridge et al., 
2007). But in cheek SCC, the aggressive behaviour is described with higher recurrence 
rate and spread of tumor that is facilitated by lack of an effective anatomic barrier 
(Strome et al., 1999; Lee et al., 2005; Lin et al., 2006; Huang et al., 2007). Distinct 
behaviours between these 2 subtype of OSCC has been further explained  in proteomic 
level by He et al. (2004) and Chen et al. (2004a) showed that tongue and cheek SCC are 
involved in different pathways.  
 
Though cancer is considered generallyto have only losses of co-operative cell 
behaviours that normally facilitate the multicellularity (formation of tissues and organs), 
but they arealso characterized by multiple dys-regulated pathways that control 
elementary cellular processes such as cell growth and cell fate (Kreeger and 
Lauffenburger, 2010). These dys-regulationof cell signaling pathways are usually 
resulted from the accumulation of genetic alteration in cancer cells particularly by the 
disruption of oncogenes and tumor suppressor genes in normal cell regulation (Bild et 
al., 2006a). Infact, studying a large number of biological pathways may allow the notion 
to recognize a series of oncogenic pathway signatures that are resulted from genetic 
instability (Bild et al., 2006b). Therefore, a better understanding of the pathways of 
various genes involved in carcinogenesis will facilitate the improvement of diagnosis, 
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therapeutic management and anticancer drug discovery in the war against cancer (Zhao 
et al., 2009; Liu et al., 2010; Nambiaret al., 2010). 
 
Rationale of the current study: 
Unlike Asian countries, implementation of molecular cytogenetic technique in field of 
cancer research is widely established in Western nations (Varella-Garcia, 2003; 
Gasparini et al., 2007). Indeed in Malaysia too, these attempts were rarely reported for 
oral cancer. Embarking on the applications of genome wide screening using higher 
resolution array CGH, we could expect the identification of highly accurate localization 
of specific genetic alteration that is associated with tumor progression (Kallioniemi, 
2008). This would offer a better understanding on cancer development and may be 
regarded as an improved tool for clinical management of cancer in the area of 
developing diagnostic and therapeutic targets (Shinawi and Cheung, 2008).  
 
Previous studies have shown that oral cancer like tongue and check can occur in 
different subsites and can behave differently (Chen et al., 2004a; He et al., 2004). In this 
perspective, there is a need to perform genome wide screening on exploring the causes 
of these two different subsites (tongue and cheek). By conducting this attempt, a new 
set of gene with copy number variations in OSCC could be discovered and as such 
development of suitable biomarkers for improving the diagnostics can be pursued. 
Nevertheless, the findings from the present research could be made possible to compare 
the available databases so far to target the genes that are involved in multiple pathways 
that are significant for oral cancer. Therefore, in order to fully understand the OSCC 
behaviour, there is a necessity to look into the chromosomal alterations and gene 
pathways involved with oral cancers at different sites.  
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Aim: 
The basic aim of the present study is to determine the chromosomal aberrations and 
gene pathways involved in tongue and cheek SCC using ultra-high resolution array 
CGH. 
 
Specific objectives of the currentresearch: 
i. To determine the DNA copy number aberrations in tongue and cheek SCC using 
array CGH technology. 
ii. To identify the genes involved in tongue and cheek SCC using array CGH 
technology. 
iii. To determine the significant pathways involved in tongue and cheek SCC using 
pathway analysis software. 
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2.0 Literature Review 
According to World Health Organization (WHO), cancer is defined as a group of 
disease in which the cells grow abnormally, uncontrollably and enable invasion to 
others part of the tissue leading to metastasis (http://www.who.int/en/). Any cancer 
occurring within the oral cavity is defined as oral cancer 
(http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002030/). 
 
2.1 Epidemiology of oral cancer: 
2.1.1 Incidence 
Oral cavity cancer is ranked as the 12
th
 most common malignancy in the world (Parkin 
et al., 1999; Scully and Bedi, 2000). Oral cavity cancers are one of the most common 
malignancies found worldwide.There were 263,900 new cases of oral cancer and 
128,000 deaths worldwide in 2008 according to Global Burden of Cancer 
(GLOBACAN) (Jemal et al. 2011). In United States of America, oral cancers are 
accounted for 30,100 cases and 7,800 deaths, representing almost 3% of all cancer 
(Greenlee et al., 2001). In 2004, around 67,000 new cases of oral cancers were reported 
in countries of European Union and ranked as 7th most common malignancy (Boyle and 
Ferlay, 2005). Oral cancer incidence and mortality rates have either been stable or 
increasing in the last four decades. A sharp increase in oral cancer incidences were seen 
in countries like Germany, Denmark, Scotland, Central and Eastern Europe, Japan, 
Australia, New Zealand and also among  non-white populations in the United States 
(Stewart & Kleihues, 2003).  
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The developing countries account for almost two-thirds of total oral cancer cases and 
accounts for an average of 200,000 deaths annually (Stewart & Kleihues, 2003). Among 
the Asian countries, India has the highest incidence of oral cancer with more than 
100,000 new cases annually. In Malaysia, the first incidence of oral cancer was reported 
in 1966 by Hirayama (1966) where the incidence rate of oral and pharyngeal cancer was 
3.1 per 100,000 populations. The Malaysian National Cancer Registry (MNCR) has 
categorized oral cavity cancers into three distinct groups; namely mouth, tongue and lip 
cancers (Lim et al., 2008). If the incidences of these three cancers (mouth, tongue and 
lip cancer) were counted as one, the rank of oral cavity cancers will be higher and 
definitely comparable with incidence rate reported in other studies worldwide (Lim et 
al., 2008).   
 
2.1.2 Gender, Ethnic and Age distribution 
Warnakulasuriya (2009b) reported that oral cancer is more common in men than women 
with a ratio of 1.5:1 in most countries of the world. Similarly, in South and Southeast 
Asian countries such as India, Sri Lanka, Pakistan and Taiwan, the incidence of oral 
cancer is higher in men. In the year 2003 and 2005, the mouth cancer was ranked as the 
22
nd
 and 15
th
 most common cancer for males and females, respectively in Malaysia 
(Lim et al., 2008). During these years, tongue cancer was ranked at 17
th
 and 21
st
 among 
males and females, respectively. 
 
In USA, oral cancers are reported more frequently in blacks than in whites, ranking 6th 
most common among blacks and 11th among whites (Day et al., 1993). There were a 
sharp incidence and mortality rate increment of oral cancer in Germany, Denmark, 
Scotland, Central and Eastern Europe, Japan, Australia, New Zealand and USA among 
the non whites (See review; Stewart and Kleihues, 2003). Warnakulasuriya and Johnson 
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(1996) pointed out that oral cancer existed to be most prevalent in areas with high Asian 
population such as in India and Taiwan. Interestingly in Malaysia, a marked variation in 
the incidence of oral cancer was observed among the different ethnic groups that make 
up the Malaysian population. According to Malaysia National Cancer Registry (MNCR) 
in the year 2003, oral cancer was ranked at 6
th
 position and 3rd most common cancers 
for Indian males (ASR=7.2) and females (ASR=16.5). Meanwhile, tongue cancer was 
ranked as the 9th most common cancer for Indian males (ASR=6.4) and females 
(ASR=6.8) (Lim et al., 2004). These findings confirm the results of study by Zain and 
Ghazali (2001), which indicated that ethnic Indian group, has the highest risk for oral 
cancer among the Malaysian population. This is because of the fact that Indian 
populations were highly involved in practice such as betel quid chewing as compared to 
other ethnic groups (Zain and Ghazali, 2001). 
 
Incidence of oral cancer is more common with increasing age in all countries 
(Warnakulasuriya, 2009b). Approximately 95% of oral cancer cases are reported in 
people who are older than 40 years old (Warnakulasuriya, 2009b). Based on the 
database of National Cancer Institute's Surveillance, Epidemiology and the End Results 
(SEER) from the year 2000-2004, the median age of getting oral cancer was 62 in 
United States (SEER Cancer Statistics Review, 2009). However, there is a gradual 
increasing trend in incidence of oral cancer cases and mortality rate in young adults in 
European countries and United States (Macfarlane et al., 1994; Shiboski et al., 2005). 
According to the study done by British Dental Association (2000), approximately 6% of 
oral cancers were diagnosed in younger patients less than 45 years of old. In Indian 
subcontinent which has one of the highest oral cancer prevalence showed that the oral 
cancer usually occurs prior to the age of 35 mainly due to the tobacco chewing practice 
(Johnson, 1991). Besides that, in Sri Lanka, almost 5% of oral cancer is diagnosed in 
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young patients (Siriwardena et al., 2006).  In Malaysia, MNCR reported that there was 
an exponential increase of oral cancer incidence after the age of 40 years old for both 
sexes (Lim et al., 2004). 
 
Most of the studies on oral cancer uses the guideline provided by the International 
Classification of Disease (ICD) which normally include cancer of the lip (C00), tongue 
(C01-02), gum (C03), floor of the mouth (C04), palate (C-05) and other and unspecified 
parts of the mouth (C06) (Sugerman and Savage, 1999). But several other studies have 
excluded lip, salivary glands and other pharyngeal site in their classification of oral 
cancer (Moore et al., 2000; Zain and Ghazali, 2001). In some other cases, researchers 
have included the sub sites within the oral cavity such as salivary glands and other 
pharyngeal sites (ICD-10:C11-C13) (Parkin et al., 1999; Warnakulasuriya, 2009b; 
Ferlay et al., 2010).  
 
2.2 Clinical and Histological characteristics of oral cancer 
2.2.1 Subsites of oral cancer (ICD-10) 
Oral canceris classified according to anatomical subsites of the International 
Classification of Disease (ICD-10), a coding system that was developed by World 
Health Organization (WHO) (Johnson, 2003). Accordingly the intra-oral sites 
corresponding to the ICD-10 code are; C00 (lip), C01 (base of tongue), C02 (other and 
unspecific parts of tongue), C03 (gum), C04 (floor of mouth), C05 (palates) and C06 
(other and unspecific parts of the mouth) (Johnson, 2003). 
 
 
 
 
11 
 
2.2.2 Clinical appearance 
At the initial stages, carcinomas may be asymptomatic (Scully et al., 1986). They may 
present as indolent ulcers that fail to heal (Scully et al., 1986). In other cases, it may 
present as an erytholeukoplastic lesion consisting of red and white areas with slight 
roughness that is well demarcated (Mashberg et al., 1989). The adjacent soft tissues 
may also show induration (Bagan et al., 2010). In the advanced stages, it may be 
manifested as characteristic features of malignancy including ulceration, nodularity and 
fixation to underlying tissues (Scully and Bagan, 2009a). The late stages may present as 
ulceration with irregular floor and margins. The patients may experience severe pain 
radiating to ipsilateral ear in late stages (Bagan et al., 2010). Bagan et al. (2010) also 
described in the advanced stages the oral cancer may present as exophytic tumor with 
warty surfaces and poorly defined boundaries. 
 
2.2.3 Histological appearance 
More than 90% of oral canceris oral squamous cell carcinoma (OSCC) where it is 
derived from the surface epithelium and extends from the basement membrane which 
would replace the normal epithelium. Since basement membranes are being penetrated, 
the carcinoma will invade the underlying connective tissues (Nagpal and Das, 2003; 
Silverman, 2003). Pindborg et al. (1997) defined OSCC as a malignant epithelial 
neoplasm that exhibits squamous differentiation as characterized by the formation of 
keratin and/or the presence of intercellular bridges. OSCC can be graded 
histopathologically into well, moderate and poorly differentiated lesions. These grading 
is based on the method originally as described by Broder's. This method takes into 
account the subjective assessment of the degree of keratinization cellular and nuclear 
pleomorphism and mitotic activities (Pindborg et al., 1997). 
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2.3 Etiological factors: 
Oral cancer is usually related to the chronic exposure of oral mucosa to a range of 
mutagens like chemical, physical and microbial agents which results in DNA mutation 
of oral keratinocytes (Zain and Ghazali, 2001; Scully and Bagan 2009b). Well 
documented etiological factors like tobacco smoking, excessive alcohol consumption 
and betel quid chewing are known to cause oral cancers either independently or 
synergistically (Blot et al., 1988; Zain and Ghazali, 2001; Warnakulasuriya, 2009b). 
 
2.3.1Tobacco smoking 
Cigarette smoking has been identified as an independent risk factor for oral cancer and 
all forms of tobacco including smokeless tobacco have strongly been associated with 
oral cancers (International Agency for Research on Cancer, 1986; Rodu and Jansson, 
2004). Worldwide, the risk of getting oral cancer in smokers is 7-10 times higher than 
that for non-smokers (Warnakulasuriya et al., 2005). Case control study of Rodriguez et 
al. (2004) showed that heavy smokers have an odd ratio of 20.7 of getting oral cancers. 
Besides that, another study conducted by Neville and Day (2002) showed that smokers 
have five to nine times higher chances to develop oral cancer compared to non smokers. 
 
The reasons to cause oral cancer by tobacco smoking can be explained by the fact that 
there are more than 300 carcinogens found in tobacco smoke. Some of the most 
important carcinogens are polycyclic aromatic hydrocarbons (PAH), benzo-α-pyrene, 
tobacco specific nitrosamines including nitroso-nor-nicotine (NNN) and 4-
(methylnitrosoamino)-1-(3-pyridyl)-1 butanone (NNK) that exert as DNA adducts and 
attack oral mucosa epithelium leading to chromosomal damage and DNA mutation. For 
example: change of guanidine to thymidine transversions (Hecht, 2003; IARC, 2004). 
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Recently, few studies performed by using genome wide screening was conducted on 
oral cancer patients. One study reported frequent deletion of CDKN2A (p16
INK4
) in 
smokers for both lung and oral cancers (O'Regan et al., 2006) when compared to non-
smokers which suggested that this tumor suppressor gene play a crucial role in cancer 
formation to smokers. Besides that, Chattopadhyay et al. (2010) reported the synergistic 
effect of the tobacco and betel quid chewing resulted in chromosomal aberrations in 
esophageal squamous cell carcinoma (ESCC) such as amplification of chromosomes in 
1p, 1q, 2q, 3q, 5p, 6p, 8q, 9q, 11p, 11q, 15q and deletion of chromosome in 3p, 8p, 9p, 
13q, 18q. 
 
2.3.2 Excessive alcohol consumption 
Regular and excessive alcohol consumption proved to increase the risk of oral cancer as 
it accounts for 7-19% of cases worldwide (Petti, 2009). A review paper by Petti (2009) 
showed that moderate alcohol drinker have 2-3 fold higher for getting oral cancer 
compared to non-drinkers. The association of alcohol intake and tobacco smoking for 
the causage of cancer has been documented for more than 50 years ago (Rothman and 
Keller, 1972; Blot et al., 1988). The risk is higher by 48 fold with synergistic effect 
between these 2 independent risk factors on oral cancer development, which accounts 
for more than 75% of the oral cancer cases reported in developed countries (IARC, 
1990; Rodriguez et al., 2004). This can be explained biologically by the ability of 
alcohol to remove lipid content on the membrane and causing it to be more permeable 
for tobacco carcinogen which exert as DNA adduct in oral mucosa and promote oral 
carcinogenesis (Ogden and Wight, 1998; Wight and Ogden, 1998). 
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Studies of Garro et al. (1986) and Mufti (1992) have demonstrated the mutagenic effect 
of excessive alcohol consumption that has shown to increase the frequency of chromatid 
breakage in DNA through an in vivo study. This suggests that alcohol have the ability to 
dys-regulate the DNA repair mechanism when DNA is mutated. Besides that, it was 
also reported that alcoholic drinker have 5-9 fold tendency to get tongue SCC (Herity et 
al., 1981). In fact, alcoholic drinkers in the Asian populations have a higher tendency to 
get oral cancers. This may be due to the fact that the alcoholic drinkers have inactive 
aldehyde dehydrogenase enzyme. This enzyme may have the ability to detoxify the 
acetaldehyde, a known carcinogenic agent (DNA adducts) for oral mucosa (Petti 2009).   
 
2.3.3 Betel quid chewing 
Apart from the two well documented risk habits which are tobacco smoking and 
excessive alcohol consumption, studies from South Asian countries especially from 
India and Taiwan also showed that betel quid chewing is an important risk factor to 
increase the incidence of oral cancers, since it is widely practiced in these regions (Lin 
et al., 2000; Balaram et al., 2002; Gupta and Ray, 2004; Wen et al., 2005). 
 
Studies done by Daftary et al. (1991) and Henderson and Aiken (1979) reported that the 
risk of getting oral cancer associated with betel quid containing areca nut and tobacco 
was 8-15 times higher than using quid without tobacco which is lesser by 1-4 times. The 
betel quid chewing exposes the oral mucosa to a highly reactive oxygen species (ROS) 
(Nair et al., 1987). The carcinogenic ROS and DNA adduct induce genetic instability 
and initiate tumorigenesis by causing the structural changes in oral mucosa which 
favour other betel quid compounds to penetrate the oral mucosa (Nair et al., 1985).  
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The development of OSCC due to chromosomal instability associated with betel quid 
and tobacco is largely determined by the gains in chromosomes 8q, 9q, 11q, 17q, and 
20q and most frequent losses are reported in chromosome arms at 3p which normally 
involves the inactivation of tumor suppressor genes likes FHIT, RARβ and VHL. Other 
deleted regions detected from the CGH analysis on oral cancer patients with betel quid 
chewing are 4q, 5q, 9p21-23, and 18q (Lin et al., 2001). 
 
2.3.4 Human Papillomaviruses Virus (HPV) 
Previously the occurrence of human papillomaviruses (HPV) in OSCC biopsy was 
detected using Southern Blot analysis (Villiers et al., 1985). According to zur Hausen 
(1996), HPV is the most common virus studied in relation to the head and neck tumor. 
Studies on HPV incidence and oral cancer risk exhibited a wide range which varied 
between 0 and 100% (Kozomara et al., 2005). The most common and high risk type 
HPVs found are HPV16 and 18 which encodes oncoproteins E6 and E7. These 
oncoproteins will bind to p53 and pRb, thus inactivating the tumor suppressor genes. 
These genes are normally involved in turning off the cell division of those cells with 
DNA damage. This condition could lead to genomic instability and accumulation of 
genetic changes, thus contributing to the malignant progression (Wilczynski et al., 
1998). 
 
A case control study by International Agency for Research on Cancer (IACR) have 
identified DNA of HPV in 3.9% of oral cavity and 18.3% of oral premalignant cancer 
(Herrero et al., 2003). In a Japanese population of 46 OSCC patients, 73.9% of the 
samples were found to have infected with HPV (Shima et al., 2000). Among them 
26.5% were of HPV type-16 and 73.5% were HPV type-18. Study done by Klussmann 
et al. (2009) using CGH analysis on 28 HPV related OSCC revealed that only one third 
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of them were showing gain in chromosome 3q26.3 region. Moreover, this study also 
showed that there was a high occurrence of chromosomal 16q deletion with HPV 
positive OSCC, which suggested that the FRA16D gene harboured in this region may 
increase the risk of malignancy in oral cancer (Klussmann et al., 2009). 
 
2.3.5 Genetic Susceptibility 
The genetic risk for head and neck cancer has always been reported to be associated 
with polymorphisms of drug-metabolizing enzymes (Hahn et al., 2002). This might 
influence an individual’s susceptibility to chemical carcinogenesis such as cytochromes 
P450 (CYPs) which metabolizes polycyclic aromatic hydrocarbons (PAHs) and 
glutathione S-transferases (GSTs) that are involved in the detoxification of activated 
metabolites of carcinogens (Hahn et al., 2002). Nevertheless, the three most studied 
genes for polymorphism in relation to oral cancers are GSTM1, GSTT1 and CYP1A1.  
 
In a study conducted among Indian patients with GSTM1 null (deletion) genotype were 
found to have an OR of 1.3 (95% CI 0.37-4.82) (Sreelekha et al., 2001). Similarly 
among the Japanese patients, a significant 2.2-fold increased risk (95%CI 1.4-3.6) was 
found for individuals with null genotype (Sato et al., 1999). Another study performed 
among the Thais also found a 2.6-fold higher risk (95% CI 1.04-6.5) (Kietthubthew et 
al., 2001). However, studies among the Western population found the other way around. 
A study conducted at France by Jourenkova-Mironova et al. (1999) found that there was 
no association between GSTM1 null genotype with oropharyngeal cancer risk (OR 0.9, 
95% CI 0.5-1.5).  
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GSTT1 null were also found to confer an increased risk of 2.5 (95%CI 0.28-21.71) 
among the Indians (Sreelekha et al., 2001). However, Katoh et al. (1999) in their study 
among the Japanese found no association among the null genotype with oral cancer (OR 
0.68, 95% CI 0.38-1.22) and this finding is supported by Kietthubthew et al. (2001) in 
their study among oral cancer patients in Thailand. 
 
CYP1A1 polymorphism were found to confer an OR of 5.3 (95%CI 1.03-26.28) among 
the Indians (Sreelekha et al., 2001) which was supported by Park et al. (1997) in their 
study among Caucasian oral cancer patients where a significant 2.6-fold increased risk 
(95% CI 1.2-5.7) was found. This finding is further supported by Sato et al. (1999) who 
found a significant 2.3-fold increased risk (95% CI 1.1-4.7) in their study among 
Japanese oral cancer patients.  
 
However, a preliminary study on 81 Jakarta oral cancer patients showed a lack of 
evidence to support any association between polymorphisms of GSTM1, GSTT1 or 
CYP1A1 with oral cancer occurrence (Amtha et al., 2009).   
 
2.3.6 Diet and Nutrition 
Researchers have attempted to investigate the relationship between dietary intake and 
the occurrence of oral cancers since 1977 (Graham et al., 1977). In mid of 1990’s, Winn 
(1995) reported that dietary and nutritional factors have implication in oral 
carcinogenesis. Studies by La Vecchia et al. (1997) estimated that approximately 15% 
of oral cancer cases were caused by imbalances or deficiencies dietary in European 
population. According to the study done by Petridou et al. (2002), the vegetables, fruits, 
micronutrient, dairy products and olive oil can play a vital role in protecting against oral 
cancer through high consumption of riboflavin, iron and magnesium. Berger et al. 
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(1991) has suggested that Vitamin-A could act as a potential protective source from 
carcinogenesis and lack of them in the diet can lead to metastasis. According to these 
Berger and his team, Vitamin-A has the ability to inhibit DNA synthesis and can 
influence the epidermal growth factor receptors which are over expressed and can cause 
tumor cell proliferation through the effect of protein kinase C. Another study by 
Garewal (1995) mentioned that antioxidant nutrients such as ß-carotene and vitamin-E 
could play a vital role against oral cancers based on the evidence from animal model 
systems and laboratory studies.  
 
2.3.7 Mouthwash 
Earlier studies showed that there are some controversies arising from the use of alcohol 
containing mouthwashes and oral cancer (See review Warnakulasuriya, 2009a). For 
example, a study conducted by Winn et al. (1991) showed that frequent use of 
mouthwash containing alcohol with concentration of greater than 25% had a higher risk 
to get oral and pharyngeal cancer. Similarly, McCullough and Farah (2008) showed that 
alcohol containing mouthwashes contributes to oral carcinogenesis. However, a recent 
meta-analysis conducted by La Vecchia (2009) conﬁrmed that there are no excess risks 
involved in getting oral cancer either using mouthwash with or without ethanol. 
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2.4 Genetic Alteration 
Genetic instability is a hallmark of most cancers. Chromosomal instability is 
characterized by the changes in chromosomal structure (inversions, point mutations and 
translocations) (Albertson et al., 2003; Perera and Bapat, 2007) and numerical 
(amplification and deletions) where these events are able to cause uncontrolled cell 
proliferation, altered cell morphology, and tumor progression (Lengauer et al., 1998; 
Gollin, 2004). Though there are various forms of genomic instabilities, chromosomal 
instability (CIN) and microsatellite instability (MIN) are the common ones to be 
encountered in cancer (Loeb, 2001; Negrini et al., 2010).  
 
There are two categories of structural aberrations, namely balanced (reciprocal) and 
unbalanced (non-reciprocal). Reciprocal alteration is the exchange of chromosome parts 
between non-homologous chromosomes and no genetic content is lost or gained 
(Albertson et al., 2003). However, in non-reciprocal alteration, the exchange is unequal, 
resulting in extra or missing copies of genes and chromosomes regions (Albertson et al., 
2003). Another type of genomic instability is known as MIN, which refers to the base 
pair mutations that are caused by the defection of the mismatch, base excision and 
nucleotide excision repair genes at the nucleotide level. These alterations happening 
would enable to cause expansion or contraction of the number of oligonucleotide 
repeats at the microsatellite sequences (Lengauer et al., 1998). 
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Epigenetic alteration involves modification of DNA transcription via DNA methylation 
and chromatin components such as histones (Baylin and Ohm, 2006). These factors do 
not change the DNA code, but they make accessibility of DNA for transcription which 
leads to the transcriptional silencing of tumor suppressor genes (Esteller and Herman, 
2002). Nevertheless, the gene expression aberrations that arise due to genetic and 
epigenetic changes allow cells to have selective growth advantage and results in 
uncontrolled tumor growth (Baylin and Ohm, 2006; Jones and Baylin, 2007).  
 
2.5 Chromosomal Instability (CIN) 
Chromosomal instability (CIN) is regarded as “mutator phenotype” and is demonstrated 
by the cells that have increased amount of unstable chromosome content which arise 
from the abnormal mitosis as compared to their normal counterparts (Loeb, 2001; Chi 
and Jeang, 2008). The features of the unstable content include DNA translocation, 
aneuploidy (loss/gain of whole or portions of chromosome), changes in gene copy 
number and chromosomal rearrangement (Lobo, 2008). 
 
All human cancer types undergo chromosomal and genetic aberrations, including OSCC 
(Reshmi and Gollin, 2005). It was established that the role of chromosomal instability 
contribute to tumor initiation and progression (Michoret al. 2005). After his observation 
on chromosomal aberrations in tumor cells, Michor et al. (2005) suggested CIN as the 
central issue in cancer biology. The chromosomal aberrations will hijack the normal 
cellular processes; such as cell signaling, replication, and apoptosis, causing an 
uncontrollable cell proliferations and defects in DNA repair mechanisms which are 
responsible for tumorigenesis (Loeb et al., 2003).  Studies have been reported that over-
expression of aurora kinase A-(AURKA) gene in cancer may lead to failure in 
maintaining the stablechromosomal contents due to the defective centrosome 
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maturation, bipolar spindle assembly and mitotic entry (Katayama et al., 2003; Vader 
and Lens, 2008). 
 
Some of the defective functioning of mitotic checkpoint machinery such as 
centrosomes, microtubules, kinetochores, loss of spindle check point, abnormalities of 
double strand break repair and temolere dysfunction in mitosis have been shown to alter 
chromosome number and its structure which contributes to chromosomal instability 
(Reshmi and Gollin, 2005; Chi and Jeang, 2008; Schvartzman et al., 2010). This 
defective mitotic machinery is mainly due to the failure in separation of sister 
chromatids, before microtubule attachment during cell division (Schvartzman et al., 
2010).  
 
The involvement of extrinsic cytoskeletal aberrations such as multipolar spindles 
(Saunders et al., 2000) and alterations in centrosome number (Gisselsson et al., 2002) 
which enabled to induce CIN were detected in few oral cancer studies. For example, 
Saunders et al. (2000) observed various degrees of multipolar spindles from OSCC cell 
line such as different level of chromosomal capture and alignment which enabled to 
induce CIN. Another study by Gisselsson et al. (2002) has shown the alterations of 
centrosome number in oral cancer where they suggested that the prevention of 
cytokinesis caused by the internuclear connection has lead to duplication of both 
chromosome and centrosome number.  
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Another factor that promotes CIN is increased expression of centrosomal protein during 
cell divisions which are actually regulated by checkpoint kinase such as CHK1 and 
CHK2. This phenomenon is caused by the over duplication of centrosomes during a 
single cell cycle and the failure of cells to undergo proper cytokinensis will lead to 
excessive number of centrosomes (Chi and Jeang, 2008). These genetic changes could 
contribute to different phenotypes that can result in increased malignancy and more 
aggressive behaviour (Weinstein, 2002; Chi and Jeang, 2008).   
 
2.6 Oncogene and Tumor Suppressor Gene 
In tumorigenesis, gene amplification is considered as an important step involved in  
oncogene activation (Coleman and Tsongalis, 2002) and loss of chromosomal materials 
will most likely harbour the inactivated tumor suppressor gene (TSG) (Frohling and 
Dohner, 2008). A plethora of genetic events leading to activation and inactivation of 
oncogenes and TSG, respectively are involved in the pathogenesis of OSCC (Argiris et 
al., 2008). 
 
2.6.1 Oncogenes 
In general, oncogenes are derived from gain of functions in cellular proto-oncogenes. 
This is occurred through the alteration of few common mechanisms such as mutation, 
chromosomal rearrangement (translocations and inversions), and gene amplifications 
(Croce, 2008). Oncogenes are broadly classified into six functional groups such as 
transcription factors, growth factors, growth factor receptors, chromatin remodelers, 
signal transducers and apoptosis regulator (anti-apoptotic regulator) (Croce, 2008). 
Amplification of oncogenes are usually observed during tumor progression which is 
enhanced by certain encoded proteins through checkpoints dys-regulation of the cell 
cycle (Field, 1995).Several oncogenes have been implicated for oral carcinogenesis 
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such as c-myc, int-2, hst-1, cyclin D1 and EGFR (Todd et al., 1997). Some studies have 
indicated that the epidermal growth factor receptor gene (EGFR), were over-expressed 
and amplified in oral cancers (Ishitoya et al., 1989; Chen et al., 2003). Epidermal 
growth factor receptor genes are involved in transmembrane tyrosine-specific 
phosphokinase activity in normal condition. The binding of EGF receptors to their 
ligands lead to phosphorylation of tyrosine residues EGFR to dimerization and 
activation. These would then activate two important kinase pathways and favours 
growth, invasion, metastasis and angiogenesis in oral cancer (Ciardiello et al., 2004; 
Yano et al., 2003; Kalyankrishna and Grandis, 2006).  
 
Another oncogene that is implicated in oral cancer is ERBB2 gene (Xia et al., 1997). 
This gene is activated through heterodimerzation with other receptors for activating the 
mitogen activated protein kinase (MAPK) or phosphatidylinositol 3-kinase (PI3K)-AKT 
activated pathways. This gene will enhance tumor invasion, cell proliferation, 
differentiation, adhesion and cell migration in cancer (Olayioye et al., 2000). Callender 
et al. (1994) studies reported an amplification of Cyclin D1 which was associated with 
tumor aggressiveness and is a late event for head and neck carcinoma. The expression 
of Cyclin D1 which normally plays an important role as cell proliferation promoter in 
G1 phase of the cell cycle. However, when over expressed, Cyclin D1 has enhanced the 
cancer progression in tumorigenesis (Hunter and Pines, 1991). The importance of 
targeting oncogenes in molecular targeted cancer treatment was reported by Heinrich et 
al. (2002) and Casali and Messina (2004) in their study. In this study the investigators 
used Imatinib to affect/inhibit the KIT and PDGFR receptor kinases in chronic 
myelogenous leukemia.   
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2.6.2 Tumor Suppressor Genes 
Conversely, inactivation or deletion of tumor suppressor genes (TSG) or anti-oncogenes 
is responsible for initiating cancer progression (Mitelman, 2005). This is because tumor 
suppressor genes are negative growth regulators that regulate cellular trafficking, 
regulation of DNA damage response and apoptosis in a recessive fashion (Weinberg, 
1991). The definition of TSG is still evolving and Weinberg (1991) defined that TSG is 
a genetic element whose loss or inactivation allows a cell to display one or the other 
phenotype of neoplastic growth deregulation. The loss of function of TSG is oncogenic 
and has been documented to be the major event during carcinogenesis (Munger, 2002). 
It is common that there are few inactivated TSG in same tumors and the same 
suppressors can be found inactivated in different tumor types such as lung, breast and 
colon cancer (Sager, 1989). Loss of these genes promotes the cell cycle proliferation, 
signal transduction, angiogenesis and tumor growth (Sager, 1989). TSG are recessive 
which requires two mutated alleles for tumor formation and it was reported in a two-hit 
mechanism, proposed by Knudson in the early 1970 (Knudson, 1971). The two hit 
theory stated that both the alleles needed to be inactivated in order to promote malignant 
growth (Knudson, 2001). 
 
Kinzler and Vogelstein have categorized tumor suppressor genes into 2 groups which 
were ‘gatekeepers’/‘caretakers’ (Kinzler and Vogelstein, 1997) and ‘landscaper’ 
(Kinzler and Vogelstein, 1998). The gatekeeper genes like RB1 and TP53 function to 
inhibit the tumor growth, suppress neoplasia and promote cell death. The losses of 
function of these genes are rate-limiting in multi-stage tumorigenesis (Kinzler and 
Vogelstein, 1997). By contrast, ‘caretaker’ tumor suppressor genes such as BRCA1 and 
BRCA2 work as DNA maintenance genes to suppress growth by ensuring the fidelity of 
the DNA code through effective repair of DNA damage and maintain genome integrity 
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(Kinzler and Vogelstein, 1997; Russo et al., 2006). Landscaper’s actually work through 
a less direct mechanism by affecting tumor microenvironment in which tumor cell grow 
such as extracellular matrix (ECM) protein, cell surface markers, adhesion proteins and 
survival factors. Indeed, loss of function of landscaper TSG would lead to malignancies 
(Kinzler and Vogelstein, 1998). For example, loss of E-cadherin and alpha-catenin in 
epithelial cell junction and epithelial stromal cell interaction induce epithelial 
mesenchyme transition in carcinoma progression (Thiery, 2002). 
 
Reports suggest that loss of function of FHIT, RB1, TP53 and CDKN2A has been 
implicated in head and neck SCC (Virgilio et al., 1996; Koontongkaew et al., 2000; 
Nakahara et al., 2000). Biallelic inactivation of a specific TSG can occur through 
chromosomal allelic loss such as loss of heterozygosity (LOH)-allelic deletion, point 
mutation and deletion of both alleles (Oesterreich and Fuqua, 1999; Vogelstein and 
Kinzler, 1993; Knudson, 2001; Oster et al., 2005). Both alleles of a TSG need to be 
inactivated in order to unmask recessive mutations which have effect on cell phenotype 
(Yokota and Sugimura, 1993). Inactivation of TSGs through epigenetic mechanism 
decreases the gene expression without affecting the DNA sequence. In the epigenetic 
silencing mechanism, CpG islands located in the promoter regions is hypermethylated 
and reduces the TSGs expression (Jain, 2003). For example, Yeh et al. (2003) have 
demonstrated few hypermethylated regions containing TSGs such as CDKN2B, 
CDKN2A and TP53 related to oral cancer. In addition to two-hit hypothesis, a new 
concept of haploinsufficiency has been recently proposed (Macleod, 2000). This 
concept is related to a gene dosage effect whereby a copy-loss of a potential TSG could 
have an impact on cell phenotype (Fodde and Smits, 2002). 
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Levine (1997) described the inactivation of TSGs which leads to the evasion of cell 
from the tight cell cycle regulation and predispose to the uncontrolled cell growth and 
cell division which contributes to the malignant phenotype of cancer. Thus, loss of 
TSGs may be predictive of patient outcome (Gleich and Salamone, 2002). 
 
2.7 Carcinogenesis 
In carcinogenesis, genetic instability could influence the certain enzymes that accelerate 
the pathogenic pathways which are involved in DNA replication and repairing, 
chromosomal instability, apoptosis and cell cycle regulation in response to DNA 
damage (Beckman and Loeb, 2005). This can be seen in oral carcinogenesis, which 
results from multistep process involving the accumulation of genetic alterations 
including chromosomal aberrations, DNA mutations and epigenetic alterations (Scully 
et al., 2000; Choi and Myer, 2008). These events could disrupt the normal cellular 
processes and may lead to abnormal amplification of centrosomes, defects in DNA 
repair mechanism, uncontrolled cell proliferation and reduction of apoptosis (Weinstein, 
2002; Chi and Jeang, 2008). This condition will contribute to different phenotypic 
changes that can result in elevated malignancy and more aggressive behaviour. 
 
Cancer is a group of disease that are characterized by unregulated DNA replication, cell 
growth, cell division and survival which differs from their normal cell counterparts 
(Evan and Vousden, 2001; McSharry, 2001). Generally, cancer is the condition where 
there is a loss of co-operative cell behaviours that normally facilitate multicellularity 
which includes the formation of tissues and organs (Abott et al., 2006). Cancer cells 
become ‘deaf’ to the usual controls on proliferation and follow their own agenda for 
reproduction which is beyond the constraints of normal cells (Weinberg, 1996). It has 
been postulated that three main steps are needed for the development of cancer: 
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Initiation, Promotion and Progression (Farber, 1984; Farber, 2003). The initiation 
process starts when there are irreversible cellular changes or mutations causing DNA 
damages, which are arisen either spontaneously or induced by exposure to a specific 
carcinogen. During the initiation phase, the initiated cells are not characterized as tumor 
cells due to the fact that they have not yet acquired the autonomy of growth and the 
DNA instability may remain undetected throughout the life (Okey et al., 2005). For 
promotion stage, it is general characterized that when there is further unchecked 
proliferation of these mutated cells from the initiation phase, causes a faster increase in 
tumor size (Farber, 1984). This process can be enhanced by chronic exposure to 
carcinogenic stimuli which causes the changes of an initiated cell leading to neoplastic 
transformation to favor tumor growth (Okey et al., 2005). The final stage of cancer 
development is the progression stage where successive mutations will give rise to 
increasingly malignant sub-populations. In this stage, the pre-neoplastic cells are 
transformed to a state in which they are more committed to malignant development. 
This process involves accumulation of further gene mutations leading to heterogeneity 
in cell population (Faber, 1984). As the tumor progression advances, the cells lose their 
adherence property, detach from the tumor mass and invade the neighboring tissues. 
The detached cells will also enter the circulating blood and lymph which are then 
transported to other tissues or organs away from the primary sites, which subsequently 
grows into secondary tumors and forms the distant metastases, resulting in wide spread 
tumors (Okey et al., 2005). 
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2.8 Hallmarks of Cancer 
Hanahan and Weinberg (2000) have proposed six hallmarks for distinguishing cancer 
cells from their normal counterpart: (a) self-sufficiency of growth signals; (b) 
insensitivity to growth-inhibitory signals; (c) evasion of programmed cell death; (d) 
immortality or unlimited replicative potential; (e) sustained angiogenesis, and (f) tissue 
invasion and metastasis.   
 
2.8.1 Self-sufficiency of growth signals 
Normal cell require growth signals which are soluble and membrane bound growth 
factors, to switch the cells from quiescent state into a proliferative state (Hanahan and 
Weinberg, 2000). These growth signals are ligands of receptors that are transduced from 
cell surface receptor to activate the specific intracellular signaling pathways which 
increase the cell proliferation activities (Aaronson, 1991; Hanahan and Weinberg, 
2000). Dys-regulation of these growth signals and increase in their expression cause the 
tumor cell to become hyper-responsive and thus become an important driver of self-
sufficiency growth in oral cancer (Todd et al., 1991). For example, EGFR receptor can 
be amplified and over-expressed through the most common truncation mutation (Roger 
et al., 2005; Kalyankrishna and Grandis, 2006). Grandis and Tweardy (1993) showed 
that over expression of the EGFR and its ligand along with transforming growth factor 
alpha (TGF-α) could play a critical role in oral carcinogenesis. The binding of TGF-α to 
EGFR receptor causes cascade of intracellular signaling events such as cell 
proliferation, survival, invasion, metastasis and angiogenesis (Reuter et al., 2007). 
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2.8.2 Insensitivity to growth-inhibitory signals 
Hunter and Pines (1994) indicated that loss of expression of the tumor suppressor genes 
which encodes cell cycle inhibitory protein will enable to increase the cell proliferations 
that are mainly controlled by the growth inhibitory signals such as p53 and pRB. In 
cancer, this particular hallmark can be seen through the dys-regulated interactions 
between growth inhibitory signals and cyclin-dependent kinase (CDK), which increase 
the progression of the cell cycle (Serrano et al., 1993). Few earlier studies (Pavelic et 
al., 1996; Pande et al., 1998; Xu et al., 1998) have reported that low expression of pRB 
genes were detected in oral cancer. This indicated that loss of pRB gene have disrupted 
the cell cycle progression by increased expression of transcription factor like E2F that 
promote cell cycling. Other growth inhibitory signals such as p21 and p16 are also been 
involved in cell cycle inhibition by interacting with CDK that ultimately stop the cell 
cycle progression (Serrano et al., 1993). These reports were further supported by study 
done by Sartor et al. (1999) which revealed that the loss of p16 permits the cell cycle to 
progress uncontrollably due to binding of p16 with CDK4 and CDK6 which able to 
inhibit the cell from entering into S phase during the cell cycle. 
 
2.8.3 Evasion of programmed cell death 
Hanahan and Weinberg (2000) revealed that the ability to induce tumor growth is not 
only caused by uncontrolled cell proliferation mechanism but also the ability of tumor 
cells to eliminate them to become senescence via a process called apoptosis. Oren 
(1992) and Manning and Patierno (1996) described that cancer cell differs from their 
normal cell counterparts by increased survival and evades apoptosis. This phenomenon 
has been achieved in different ways in oral cancer and one such form is over-expression 
of Bcl-2 which acts as anti-apoptotic regulatory protein in cancer (Pezzella et al., 1993). 
Study conducted by Oliver and his colleagues (Oliver et al., 2004) suggested that Bcl-
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xL inhibition can be an effective treatment to solve OSCC patients who were cisplatin 
resistance. 
 
2.8.4 Immortality or unlimited replicative potential 
In normal condition, telomere shortens after each cell cycle and this limits the life span 
of the cells (Hanahan and Weinberg, 2000; Snustad and Simmons, 2003). Cancer cells 
have an infinite lifespan (immortal) due to the ability to replicate indefinitely by 
increasing the length of their telomeres (Hayflick, 1997). The up regulation of 
telomerase which is an enzyme to protect against telomere shortening in cancer helps 
increase the life span simply by extending the end of telomere via reverse transcription 
(Shay and Wright, 2006). Several studies have found that human telomerase catalytic 
subunit gene (hTERT) were over expressed in oral cancer which was associated with 
poor prognosis (Kannan et al., 1997; Gordon et al., 2003; Lee et al., 2001a ; Chen et al., 
2007a). 
 
2.8.5 Sustained angiogenesis 
Folkman (1990) proposed that the onset of angiogenesis was associated with tumor 
growth and metastasis. This is because tumors grow well in the presence of good blood 
supply that feeds them with nutrients through their angiogenic mechanism (Folkman, 
2006). In 1996, Hanahan and Folkman (1996) suggested that angiogenic switch is 
dependent on the balance mechanism between pro-angiogenic signals and anti-
angiogenic signals that switch from the anti-angiogenic state to pro-angiogenic state to 
form new blood vessels in cancer tissues. Angiogenic switching has been very well 
reported with tumor tissue in a study done by Udagawa et al. (2002) which showed 
there was an expansion of tumor in mice after increase in the level of VEFG through 
transfection method. In oral cancer, the expression of VEGF was reported higher than 
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normal oral mucosa tissue (Denhart et al., 1997). This suggests that angiogenesisof 
tumor tissues of oralmucosa are correlated with tumor progression and aggressiveness.  
 
2.8.6 Tissue Invasion and Metastasis 
On top of all vital hallmarks of cancer, the most important characteristic that differ 
cancer cells from their normal counterpart is the ability to perform metastasis and 
invade into surrounding tissues. Indeed, metastasis is the leading cause of death in 
cancer (Liotta, 1986; Sporn, 1996; Hanahan and Weinberg, 2000). Unfortunately the 
factors that influence invasion and metastasis are not fully understood. However, Liotta 
(1986) indicated that cancer cells must interact with matrix at many stages in its 
metastatic cascade. This is a very complex process, which involves intravasation 
through angiogenesis mechanism, extravasation and growth into the surrounding 
tissues, survival in the bloodstream, stops in a new organ (secondary organ), 
cytoskeleton remodeling, initiation and maintenance of growth and neo-angiogenesis in 
the metastatic tumor (Chamber et al., 2002). 
 
Paget (1889) had proposed the concept of “seed and soil” where the growths of the 
cancer cells were dependent on the secondary organ. However, this pattern of metastasis 
was challenged by Ewing (1928), where he suggested that organ specific metastasis was 
mainly caused by circulatory pattern between the primary tumor and secondary organs. 
Later, Thiery (2002) proposed that metastasis was associated with epithelial-
mesenchymal transition (EMT). This proposal was earlier been supported by the study 
of Gumbiner (1996) which showed that loss of E-cadherin expression during EMT leads 
to increased cell motility and invasion.  
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In oral cancer, in order for the cancer cell to invade and metastases, they need to 
degrade the basement membrane and the extracellular matrix. This degradation is 
achieved through the active extracellular protease such as matrix metalloproteinases 
(MMPs) and they may also alter several classes of proteins which are involved to 
couple with their surroundings such as cell adhesion molecules (CAMs), integrins, as 
well as loss of E-Cadherin protein in the basement membrane (Choi and Myer, 2008). 
For example, decrease expression of E-cadherin has been associated with lymph node 
metastasis in oral cancer (Diniz-Freitas et al., 2006). Besides that, many other studies 
have showed that several of the MMP genes such as MMP-1, -3, -2,-9, -10,-11 and -13 
were expressed in OSCC, which suggests that they play a role in the pathogenesis of 
OSCC (Polette et al., 1991; Gray et al., 1992; Polette et al., 1993; Kusukawa et al., 
1993; Muller, et al., 1993). This is in agreement with Jones and Walker (1997) and 
Chamber et al. (2002) studies which demonstrated that MMP expression were highly 
correlated with aggressive tumor such as oral cancer. This is because of the fact that for 
the tumor cell to disseminate, extracellular matrix (ECM) must be degraded through the 
proteolytic degradation mechanism mainly ruled by MMPs families (Thomas et al., 
1999). As metastasis is a hidden process which occurs inside the body, understanding its 
mechanism becomes a necessity for diagnosis and therapeutic approaches (Chamber et 
al., 2002). 
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2.9 Model of Oral Squamous Cell Carcinoma (OSCC) 
In 1996, Califano and Sidransky groups conducted some studies to correlate the genetic 
alterations and histological stages to establish the sequence of progression for specific 
genetic alterations in head and neck cancer (Califano et al., 1996). This study employed 
loss of heterozygosity (LOH) assay using microsatellite markers on chromosome 3p, 4q, 
6p, 8p, 8q, 9p, 11q13, 13q21, 14q and 17p13 to analyze 87 oral premalignant lesions 
which included 35 hyperplasias, 31 dysplasias and 21 carcinoma insitu (CIS) as well as 
30 invasive tissues. The results showed that there were a high frequency of LOH 
occurred in benign squamous hyperplastic lesion at chromosome 9p21 (20%), 
3p21(16%) and 17p13 (11%). Hence they concluded that these chromosomal 
aberrations were initiated at early events in head and neck cancer progression (Califano 
et al., 1996). The chromosomal aberrations (loss of chromosome 9p21, 3p21 and 
17p13) were seen frequently in benign squamous hyperplastic lesion and their 
frequencies of losses were showed an increasing progression from benign hyperplasia to 
dysplasia lesion (Califano et al., 1996). Subsequent genetic alterations were observed 
from dysplasia to CIS stage where occurrences of LOH were detected at chromosome 
11q13, 13q21 and 14q31 (Califano et al., 1996). In the later event from carcinoma in 
situ to invasive cancer, LOH were detected at chromosome 6p, 8p, 8q and 4q26-28 
(Califano et al., 1996). The important implication from the genetic progression models 
will allow us to understand better, the biological behaviour and progression of oral 
carcinogenesis, based on the identification of targeted TSGs and oncogenes in the 
multifocality of oral carcinogenesis (Califano et al., 1996).  
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Several studies have suggested that oral carcinogenesis are developed through different 
histopathological stages, beginning from premalignant, through carcinoma in situ and 
ultimately to invasive cancer which is highly related to dysplasia-carcinoma sequence 
(Sidransky, 1995; Califano et al., 1996; Garnis et al., 2004a). To reconcile this model, 
Califano and colleagues have proposed that oral carcinogenesis is resulted from 
multistep process which includes chromosomal aberrations, DNA mutations and 
epigenetic alterations (Califano et al., 1996). The hypothetical model of oral 
carcinogenesis is illustrated in Figure I. 
 
Figure 1. Hypothetical model of oral carcinogenesis. The image is reprinted with kind 
permission of the publisher. (Appendix 2.1) 
 
LOH analysis was conducted by van der Riet et al. (1994) to define more clearly the 
lost function of chromosome 9p in the early event of oral carcinogenesis. They found 
that approximately 70% of pre-invasive lesions showed an allelic loss signal on 
chromosome 9p. This suggested the inactivation of chromosome 9p as the most 
common genetic changes that occur early in the progression of head and neck tumors. In 
another study Mao et al. (1996) have performed loss of heterozygosity (LOH) assay on 
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84 oral premalignant lesions using two microsatellite markers located at chromosome 
9p21 and 3p14 and the results showed that almost 96% of oral premalignant lesions 
have yielded positive results. The genes contained within the loci of chromosome 9p21 
were found to be p16 gene (Reed et al., 1996) and the loss of this gene function occurs 
frequently in many early cases of human cancers (Rocco and Sidransky, 2001). 
 
In addition, loss of chromosome arm 3p includes FHIT and RSSF1A which are known 
TSG and these geneswere detected in oral premalignant lesions and suggest that this 
loss is an early event process in oral carcinogenesis (Mao et al., 1996a). While in the 
progression from benign squamous hyperplasia to dysplasia, loss of chromosome 17p 
was observed in LOH analysis and sequence analysis of p53 exon sequence (Califano et 
al., 1996). Besides that study of Roousseau et al. (2001) on 59 premalignant oral lesion 
tissues showed that CCND1 genes are located at chromosome 11q13. In their study this 
gene was over-expressed in almost 40% of mild dysplasia, 45% of moderate dysplasia 
and 24% of severe dysplasia oral epithelial dysplasia, when analysed through 
quantitative PCR and immunohistochemistry (IHC) study  
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2.10 Conventional Cytogenetic: 
Cytogenetic studies on solid tumors have a great impact on the site of clinical genetic 
and basic science information of solid tumors over the past two decades (Mitelman et 
al., 1997). Cytogenetics is known as the study of chromosomes in terms of “coloured 
body”, which can be divided into conventional and molecular type of analyses (Fan, 
2003). Conventional cytogenetic analyses are more advanced in hematologic 
malignancy researches which normally involve using a variety of staining methods such 
as Giemsa and Leishman staining to highlight chromosome bands to study the structure 
and numbers of chromosome (Thompson, 1997).  
 
2.11 Molecular Cytogenetic 
The molecular cytogenetic techniques are mostly involved in the analysis of 
chromosomal alterations using in situ hybridization based techniques for 
example,Comparative genomic hybridization (CGH), Fluorescent in situ hybridization 
(FISH) and technology like array CGH (Fan, 2003; Varella-Garcia, 2003). 
 
2.11.1 Comparative genomic hybridization (CGH) 
The introduction of CGH was first described by Kallionoemi et al. (1992) as a 
technique that is improved from the limitation of conventional cytogenetic analysis. 
This technique was designed to identify the regions of amplification and deletion across 
the genome in a single hybridization experiment based on the comparison of 
hybridization signal intensities.This technique has contributed the greatest impact on 
molecular cytogenetic field for solid tumors. They have not only allowed to skip the 
karyotypic demonstration and in vitro tumor cell culture but also enhanced the previous 
knowledge about targeted chromosomal aberrations to a higher level (James, 1999). In 
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addition, it allows quick detection and mapping of DNA sequence copy number 
differences of normal and abnormal gene content (Weiss et al., 1999).  
 
Most of the applications of CGH come from cancer research due to DNA copy-number 
alterations which are of pathogenic importance in cancer (Tachdjian et al., 2000). In 
addition, CGH can also be used to detect consistent recurrent chromosomal losses and 
gains in specific tumors, implication of specific genes in cancer development and 
progression, analysis of the clonal evolution of cancer in vivo, and the dissection of 
genetic changes in experimental models of carcinogenesis as well as tumor progression 
(Tachdjian et al., 2000). 
 
Despite all these benefits, CGH do have its own limitations. The disadvantages include 
failure to identify structural chromosomal aberrations such as translocation and 
inversion, as CGH can only detect the gains and loss of chromosomal aberrations 
(Lichter et al., 2000). Besides that, CGH could provide only a limited mapping 
resolution, which will decrease the sensitivity to detect the chromosomal aberrations in 
the study (Lichter et al., 2000). In addition, CGH technique has a lower resolution as its 
limited ability can only detect chromosomal aberrations in the range of 10-20 Mb 
(Bentz et al., 1998). For example, CGH has its limitation to detect the amplicon unit 
which are less than 2Mb and/or deleted regions which is at least 10Mb (Piper et al., 
1995). 
 
According to the standard CGH procedures as described by Kallioniemi (1992), 
genomic DNA isolated from test and reference samples are labelled with red and green 
fluorescent dyes, respectively. Each labelled DNA is subjected to competitive 
hybridization to normal metaphase chromosomes. The hybridization of repetitive 
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sequence is actually blocked by addition of Cot-1 DNA. The ratios of red and green 
fluorescent signals in paired samples are measured along the longitudinal axis of each 
chromosome. Chromosomal regions involved in deletion or amplification in test DNA 
appear red or green, respectively, but the chromosomal regions that are equally 
represented in the test and reference DNA appear yellow based on the comparison of 
hybridization signal intensities. 
 
CGH has proved to be a promising tool to detect chromosomal aberrations in oral 
cancer. The first CGH data in head and neck cancer was published by Speicher et al. 
(1995). In their study 13 tumor samples which included 6 pharyngeal, 3 tongue, 2 
larynx, 1 lip and 1 neck were analyzed. Later, another CGH study using 17 oral 
squamous cell carcinoma cell lines were published by Matsumura (1995). Although the 
samples involved were different but their findings were almost similar, where gains in 
chromosome 3q and losses in chromosome 3p were observed. This suggested that the 
copy number change on chromosome 3 is an important chromosomal alteration in oral 
carcinogenesis. Besides that, the CGH results from Matsumura (1995) showed that the 
common gain regions observed were chromosome 8q22-26, 3q25-27, 7p12, 11q13, 
13q33, 14q, 15q and 20q whereas common deleted regions were detected in 
chromosome 3p, 18q21, 5q21-q22, 7q31 and 8p.  
 
CGH studies of oral squamous cell carcinoma have identified non random chromosomal 
gains and losses affecting whole chromosomes of 2, 5p, 7p and 8q (Hermsen et al., 
1997; Okafuji et al., 1999). However, Okafuji et al. (1999) study allowed a more 
comprehensive analysis of chromosomal alterations compared to Hermsen et al. (1997) 
due to large number of OSCC cell lines samples which were screened for chromosomal 
aberrations using CGH. This has benefitted Okafuji et al. (1999) to identify new 
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chromosomal aberrations, where they found that deletion of chromosome 18q and 4q 
and gains of chromosome 20 that were not reported in earlier studies. Similarly, Martin 
et al. (2008) have carried out CGH study on a large cohort of 31 OSCC cell lines to 
determine the chromosomal aberrations involved in the development of OSCC and their 
findings suggested that loss of chromosome 9p and gain of chromosome 11q13 are the 
potential prognostic markers involved. Furthermore, CGH data from Martin et al. 
(2008) (gain of chromosome 3q26-qter, 8q24 and 20q12) showed a similar pattern with 
the chromosomal aberrations detected from the study of Uchida et al. (2006). 
 
Chromosomal aberrations in head and neck squamous cell carcinoma (HNSCC) 
detected using meta-analysis from a total of 13 studies revealed that the most common 
gains were at chromosome 3q26-27, 1q25-q44, 2p, 2q, 5p15, 8q24, 9q34, 11q13, 
20q12-13.2 while losses were at chromosome 3p12-24, 4q21-31, 5q21, 6p, 6q, 7q22-
qter, 8p, 9p21-24, 10q22-26, 13q, 14q, 17p, 18q 21q and 22 (See review; Gollin, 2000) 
Recent study by Tsantoulis et al., (2007) also highlighted several important copy 
number aberrations such as gains of chromosome 8q22-ter, 11q13, 17q24-25, 20q and 
loss of chromosome 3p, 4q, 5q21, 18q, 21q and 22q which were in agreement with 
previous studies. Wolff et al. (1997) were reported to be the first to perform CGH 
analysis with a combination of tumor samples (20 frozen OSCC tumor tissues and four 
tongue OSCC cell lines). Frequent gain of DNA copy number aberrations were detected 
in chromosome 3q26-27, 5p15, 9q34, 1p36.3, 8q24, 10q26, 19, 20q, 11q13, 12q24, 
15q22-24, 16p13.2, 17q, 6q26-qter, 7p22, 12p12.2-p13, 14q31-32.2, 1q32-41, 2q37, 
16q23-24 and losses were found in chromosome 3p12, 5q21 and 6q13.  
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In another study, gains of chromosome 3q21-29, 11q13, and the loss of chromosome 
8p12 were identified as independent prognostic (Bockmuhl et al., 2000). Furthermore, 
Kaplan-Meier analysis revealed that gains of chromosome 2q12, 3q21-29, 6p21.1, 
11q13, 14q23, 14q24, 14q31, 14q32, 15q24, 16q22 and deletions of 8p21-22 and 
18q11.2 were significantly associated with both shorter disease-free interval and 
disease-specific survival. Similarly, another study by Ashman et al. (2003) revealed that 
gains of chromosome 3q25-27 and deletion of 22q were significantly correlated with 
reduced disease specific survival. This study suggested that deletion of chromosome 
22q was a potential independent prognostic marker in HNSCC. The chromosomal 
aberrations detected from both studies of Bockmuhl et al., (2000) and Ashman et al., 
(2003) using CGH, facilitated the effort to create a tumor classification system for 
histological characterisation. According to this system it classifies patients into 
subgroups with different survival for different treatment and diagnosis of HNSCC. 
 
Some studies have shown that there were differences of chromosomal aberrations 
between metastasized and non metastasized OSCC. Ashman et al. (2003) study reported 
that gain of chromosome 7p and loss of 9q were significantly more frequent in HNSCC 
patients with positive lymph node metastasis. However, these findings were in 
disagreement with Bockmuhl et al. (1997) and Bergamo et al. (2000) which showed 
that gain of 7p is more common in negative lymph node metastasis HNSCC. While the 
alteration of chromosome 7p is still controversial, it is interesting to note that gain of 
chromosome 7q11.2 and 7q21 was commonly detected in metastases HNSCC 
(Bockmihl et al., 2002; Tremmel et al., 2003; Hannen et al., 2004). But in another study 
by Noutomi et al. (2006), they reported that loss of 4p was associated with lymph node 
metastasis when analysed with 35 primary OSCC tissues. While another study showed 
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that gains of chromosome 1q and 2q were detected in oral cancer patients with a clinical 
history of recurrence and metastasis (Bergamo et al., 2000).  
 
To date, there were only 2 studies that analyzed the chromosomal alterations in tongue 
SCC using CGH technique (Steinhart et al., 2001; Hannen et al., 2004). However, the 
objectives of these two studies were different. Steinhart et al. (2001) study was aimed to 
determine the copy number gains and concluded that amplification of 7q could be 
specifically linked with tongue SCC whereas, study by Hannen et al. (2004) was to 
investigate the differences of chromosomal imbalances between metastasized and non 
metastasized tongue SCC using CGH. They found that gains of chromosome 3q23-qter, 
5p, 12p and 13q21-22, 7q21, 14q and loss of chromosome 15q were more commonly 
found in metastasized tongue SCC.  
 
More than half of HNSCC tumors showed deletion of chromosome 3p and 8p and was 
associated with poor differentiation of HNSCC tumors (Bockmuhl et al., 1996; Stafford 
et al., 1999). Bockmuhl et al. (1996) indicated that loss of chromosome 3p and 9p and 
gains of chromosome 3q were highly associated with well differentiated carcinomas and 
early tumor development. However, deletion of chromosome 4q, 8p, 18q and 21q and 
amplification of chromosome 11q13, 19q, 22q were highly observed in undifferentiated 
HNSCC tumors (Bockmuhl et al., 1996). 
 
Lin et al. (2002) conducted a study to determine the chromosomal aberrations of 33 
OSCC associated with betel quid chewing and 14 OSCC associated with cigarette 
smoking. Surprisingly, most of the chromosomal alterations were found to be similar in 
these two groups but the loss of chromosome 4q and gain of chromosome 8q were 
significantly lower in betel quid chewing OSCC patients. Two years later, Lin et al. 
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(2004) subjected for chromosomal aberrations identification using CGH from OSCC 
cell lines. All these cell lines were derived from a long term areca (betel) quid chewer 
who does not smoke. It was revealed that this cell line carried unique chromosomal gain 
in 5q and loss in 6p as well as common loss in chromosome 4q and gain of chromosome 
8q and entire chromosome 20. 
 
Noutomi et al. (2006) was the first group to analyse the genetic alterations in both 
primary OSCC and adjacent dysplastic lesions using CGH. Results showed that gain of 
chromosome 8q22-23 was the most frequent alteration observed in both dysplasia and 
OSCC and this finding were supported by Abou-Elhamd and Habib (2008), suggesting 
that this genetic alteration was the earliest event in the process of oral carcinogenesis.  
 
Redon et al. (2001) performed a CGH study to compare the chromosomal aberrations 
between early stages (I and II) and advanced stages (III and IV) of OSCC. They 
observed a specific pattern of chromosomal alterations in the early stages which were 
showing gain at chromosome 11q13, 3q, 8q and loss of chromosome 3p. Besides that, 
they concluded that loss of chromosome 9p and whole chromosome 18 were indicative 
of stage III and IV tumor which were in concordance with  Brieger et al. (2003) study. 
 
Huang et al. (2002) groups have managed to construct an oncogenetic tree for tumor 
progression based on the CGH data obtained from 75 head and neck cancer. This 
oncogenetic tree model revealed that gains of chromosome 3q21-29 were important 
early chromosomal alterations among all the subsites of head and neck cancer followed 
by the gains of chromosome at 8q. Hence they occupied the position of second most 
important chromosomal alterations in early event. The later event were divided into 
three subgroups which were loss of chromosome at 3p, 9p,13q and gains at 7p, followed 
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by gains of chromosome 5p, 9qter, 17p, 8q and 18p. However, the data obtained from 
this oncogenetic tree model was masked by others subgroup of head and neck cancer. In 
2009, an oncogenetic tree model based on 97 primary OSCC samples was constructed 
(Pathare et al., 2009). This advanced oncogenetic tree model revealed multiple 
pathways of oral cancer progression and showed that the gains of chromosome 8q and 
losses of 3p were the most common chromosomal alterations in oral cancer. This model 
pointed out three progression pathways which were initiated by deletion of chromosome 
8p, another by loss of chromosome 3p and the third by gains of chromosome 11q and 
7p.  
 
The importance to detect chromosomal aberrations occurring due to the increasing 
instabilities of DNA copy number changes together with concomitant microscopic 
approaches were found to be highly correlated with phenotypic abnormalities (Skacel et 
al., 2009). Thus, this suggests that this technique has wide potential application in both 
basic research and clinical practices. 
 
2.11.2 Florescent in situ hybridization (FISH) 
Fluorescence in situ hybridization (FISH) is a molecular cytogenetic technique in which 
DNA probes are labeled with different colored fluorescent tags to detect and localize the 
presence or absence of specific regions of the genome in chromosomes (Pinkel et al., 
1986). This technique has become an increasingly important diagnostic tool especially 
in cancer research (Thompson and Gray, 1993). The advantage of using FISH as a 
cytogenetic tool is its capability to analyze chromosome instability in-situ such as DNA 
copy number at specific loci in metaphase spread and interphase nuclei (Thompson and 
Gray, 1993; Hackel and Varella-Garcia, 1997). By using FISH, other informations such 
as genomic integrity and rearrangement such as translocations can be identified which 
44 
 
otherwise are unable to detect using standard karyotyping technique (Thompson and 
Gray, 1993). FISH also allows simultaneous analysis of different probes by using 
different fluorochromes which saves time (Thompson and Gray, 1993). The other 
advantages of using FISH are that it can be applied to fixed tissues. Hence, in-vitro cell 
cultures are not required and assist researchers to understand better about chromosomal 
aberrations including the identification of genetic endpoints, which might be useful to 
be developed as a chemotherapeutic agent (Thompson and Gray, 1993). 
 
FISH technique has been applied to study chromosome aberration in many cancers 
including oral cancer.  Paradiso et al. (2002) used FISH to analyze the alterations of 
HER-2/neu gene which is frequently found to be amplified in several tumor types 
including OSCC. The gene HER-2/neu is located on the chromosome 17q12-21 and 
these genes are responsible for encoding members of the tyrosine kinase family. The 
results showed that there was high amplification of this particular gene in OSCC and 
thus it was proved that this technique could be considered as a feasible tool to be 
applied on cytological brush specimens of oral mucosa. Another FISH study conducted 
by Uzawa et al. (2007) using materials from fine needle aspiration biopsy, consisting of 
57 OSCC samples showed amplification of CCND1 and deletion of p16. This study 
thus suggested that the combination of these 2 markers can serve as better prognostic 
indicator for OSCC. Based on Uchida et al. (2006) study, FISH technique was 
employed to examine the regions of chromosome 5p and the FISH has detected 100% 
gain in this region. These results were accordance with the corresponding CGH study 
on 11 oral cancer cell lines. The results from this study showed there was a signiﬁcant 
correlation between the gains of chromosome 5p indicating chromosomal aberration of 
5p involved in oral cancer progression (Uchida et al., 2006). 
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2.12 “Omic” Profiling 
Human Genome Project which was completed in the year 2004 has successfully 
identified a total of 24,500 genetic codes (International Human Genome Consortium, 
2004). This achievement has resulted in the advancement of high throughput 
technologies. One such technological development was “omic” profiling, which has 
enhanced the large scale discovery of genes that are disrupted in cancer and pathways 
which favoured the better understanding of the biology of cancer progression (Baak et 
al., 2003; Nagaraj, 2009). With the introduction of high throughput technologies 
coupled with sophisticated bioinformatic tools for complex data analysis have enabled 
us to provide a comprehensive and systematic “omic” profiling to examine genes 
interaction within the biological pathways and network in cancer genomics study 
(Martin and Nelson, 2001). Through this, understanding of the mechanism behind 
aberrations leading to carcinogenesis can be improved (Martin and Nelson, 2001).  Due 
to the complex nature of cancer, “omic” technologies take a central place in discovering 
new biomarkers that are important for developing new diagnostic and therapeutic 
strategies (Garnis et al., 2004a). The “omic” technologies include genomics (the study 
of the human genome), trancsriptomics (gene expression) and proteomics (the analysis 
of the protein complement of the genome). These technologies play an important role to 
reveal the mechanism of the cellular constituents in cancer cell and how they interact to 
produce cellular phenotypes through the information encoded from these high-
throughput technologies (Nagaraj, 2009). One of the best genomic technology is the 
array CGH. 
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2.12.1 Array CGH 
Array CGH is a high throughput technology where the metaphase chromosomes of the 
conventional CGH technique are replaced by high density array elements, which are 
comprised of genome sequences of DNA as the target for analysis (Lucito et al., 2003). 
This technology is more advanced whereby it provides particular biological aspects of 
gene that resides within regions involved in copy-number alteration. The information of 
the probes/clones sequence that is spotted onto glass microscope slide (array) can be 
translated into genes by matching with the genome database via sophisticated software. 
Thus this technique can easily determine and pinpoint the candidate genes that are 
responsible for cancer and for unknown genetic diseases (Inazawa et al., 2004; 
Lockwood et al., 2006). 
 
The limitations from conventional CGH can be overcome using array CGH (Inazawa et 
al., 2004; Pinkel and Albertson, 2005; Kallioniemi, 2008; Theisen, 2008; Shinawi and 
Cheung, 2008). For example, array CGH has more significant advantages in terms of 
higher resolution and throughput with possibilities for automation, robustness, 
simplicity, high reproducibility and precise mapping of alterations compared to 
cytogenetic method (Inazawa et al., 2004; Kallioniemi, 2008; Shinawi and Cheung, 
2008). The resolution of array CGH is theoretically higher than CGH due to the smaller 
size of DNA probes in array CGH, where the level of resolution is determined by the 
size of nucleic acid targets and the density of coverage over the genome (Bejjani and 
Shaffer, 2006). Array consisting of 60 mer oligonucleotide offer a greater sensitivity 
and specificity in detection of copy number alterations (Curtis et al., 2009).  Besides 
that, the ultimate goal to use array CGH in research is to pinpoint the locations of 
cancer-associated genes and to understand the association of specific genetic changes or 
patterns of changes to know tumor characteristic, and tumor progression. This will 
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facilitate the discovery of new markers for tumor progression and identification of 
predictive and prognostic markers in cancer (Kallioniemi, 2008; Shinawi and Cheung, 
2008). However, array CGH has its limitations such as it is unable to detect balanced 
rearrangements such as translocations and inversions, but could only detect copy 
number imbalances relative to other DNA regions and the cost to run an experiment 
using high resolution array CGH is relatively higher. Moreover, the nature of tissue 
heterogeneity reduces the sensitivity of copy number aberrations by shifting the reading 
of signal ratio due to contamination of noncancerous cell in tumor samples (Lockwood 
et al., 2006). 
 
The application of array CGH for DNA number "signatures" or profiling has been 
carried out in various cancer researches (Bejjani and Shaffer, 2006). The first oral 
cancer array CGH data was published by Redon et al. (2002) where they constructed a 
bacterial artificial chromosome (BAC) array CGH which was derived from 85 clones 
with a higher coverage for chromosome 3q25-qter region. Through the screening of 
head and neck cancer cell lines by house array CGH, they discovered a high level 
amplification of narrow chromosome 3q25.3 which comprised of clone RP5-854L10 
and RP11-197N19. 
 
One year later, Garnis et al., (2003) have constructed a high resolution array CGH using 
a tiling set of 535 human BAC that cover almost the whole chromosome 3p which were 
applied to 20 OSCC tissues. Their results showed that there is a deletion of chromosome 
3p14 which contains FHIT genes, a known predictor of poor outcome in oral cancer. 
Furthermore, they managed to detect novel chromosomal deletion regions in 3p22, 
3p24, 3p26 and were the first to report the detection of chromosomal gain in 
chromosome 3p. Subsequently, Garnis et al. (2004c) carried out genome wide screening 
48 
 
on 20 OSCC tissues, focusing on a region at chromosome 8q22 with their newly 
developed array CGH derived from 165 BAC clones representing chromosome 8q21-
24. Through the application of array CGH, they identified a recurring amplified region 
of chromosomal 8q22 which contained LRP12 gene. Gene expression analysis revealed 
this gene is a potential oncogene for oral cancer. In order to further identify 
chromosomal alterations in oral cancer, Garnis et al. (2004b) designed an oral cancer 
specific human BAC array for CGH analysis. This designed array contained 223 BAC 
clones where 135 clones were mapped to regions commonly altered in oral cancer 
which included 3p13-14, 3p24, 4q28, 7p11, 8p23, 9p22, 11q13, 13q21and 17p13. 
Although coverage of selected chromosomal region was smaller, this study marked the 
first step in the construction of commercial oral cancer specific array CGH. 
 
It is interesting to note that Snijders et al. (2005) hypothesized that rare amplicons tend 
to be informative for tumor growth. They performed a genome wide screening using 
high resolution array CGH derived from 2464 BAC clones, on 89 OSCC tissues taken 
from 4 different sites in oral cavity (tongue, cheek, gum and floor of mouth) and 
focused on narrow regions of gene amplification to discover genetic pathways involved 
in OSCC carcinogenesis. They managed to detect amplified genes involved in integrin 
singaling, survival, adhesion and migration as well as hedgehog and notch signaling 
pathways. The decision to select minimum common regions and match with gene 
expression data enabled Snijders et al. (2005) to identify candidate driver genes located 
in the amplicons. In the same year, Baldwin et al. (2005) carried out the first whole 
genome wide screening with 32433 BAC clones tiled across the genome to hybridize 
with chromosomal aberrations in 20 formalin fixed paraffin embedded OSCC tissues. 
They reported several novel chromosomal aberrations which included gain of TRIO 
gene located in chromosome 5p15.2 and 9 other matrix metalloproteinase (MMP) genes 
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(MMP7, MMP20, MMP27, MMP8, MMP10, MMP1, MMP3, MMP12, MMP13) 
within an amplicon located in chromosome 11q22.3. 
 
Due to the increase in OSCC incidence among younger patients, O’Regan et al. (2006) 
conducted a study to identify chromosomal alterations differences between oral cancer 
patients younger than 40 years old against patients aged 40 years and above. The results 
showed that deletion of p16 (chromosome 9p21), MSH3 (chromosome 5q11.2-13.2) 
and APC (chromosome 5q21-22) were completely absent in the younger group but was 
present in more than 50% among the older group. A unique study conducted by Chen et 
al. (2004), used array CGH to investigate the genetic profiles of 60 microdissected 
OSCCs in betel quid users and non users. The results from this study showed that gain 
of EXT gene and loss of FHIT gene were significantly higher in betel quid users as 
compared to non betel quid users. Another study investigated the chromosomal 
aberrations between smoker and non smokers who diagnosed with OSCC (O'Regan et 
al., 2006). However, this study only revealed that young OSCC smokers showed few 
genomic changes compared to older smokers. 
 
A study by Liu et al. (2006) compared the genomic alterations in 8 pairs of 
microdissected tissues from primary OSCC and matched metastatic lymph nodes which 
revealed that genetic alterations for TGFβ2, CRBP1, PIK3CA, HTR1B, HRAS, ERRB3 
and STK6 genes were significantly different between primary OSCC and the associated 
metastases. Similarly, Chen et al. (2004) also performed genome wide screening to 
detect the genomic alterations for metastasizing and non metastasizing OSCC. This 
study revealed that gains of EGFR genes were occurring at chromosome 7p; FDF4, 
CCND1 and EMS1 genes at chromosome 11q13 and AIB1 genes at chromosome 20q. 
Ultimately this study showed that all these genes were significantly associated with 
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metastasis OSCC. Another study carried out by Sparano et al. (2006) have attempted to 
narrowed down the previously published amplified regions by array CGH to smaller 
regions intended for yielding shorter lists of candidate genes. For example, the 
published region was from chromosome 5p14-15.3 (22.2 Mb), and they narrowed the 
documented chromosomal alterations to a minimal region which is chromosome 
5p15.33 (0.4 Mb). Amplification of chromosome 11q13 in oral cancer have been well 
documented and to characterize the 11q13 amplicon in detail, Freier et al. (2007) have 
used matrix CGH microarray containing BAC clones derived from chromosome 11q13. 
They attempted this approach in 40 OSCC tissues. They showed that the genes, EMS1 
and SHANK2 which were known as cytoskeleton associated proteins. These genes were 
amplified within the CCND1 amplicon, suggesting that these proteins coupled with 
CCND1 genes cooperatively will contribute to OSCC pathogenesis.  
 
Instead of analyzing the chromosomal aberrations for OSCC in all the studies described 
above, Garnis et al. (2009) have attempted to study the genome analysis of a cohort of 
86 oral lesions with longitudinal follow up. Samples taken in their study included 62 
oral premalignant lesions (OPL) and 24 OSCC. They used a tiling array CGH which 
comprised of 26363 overlapping BAC clones covering the entire human genome. 
Garnis et al. (2009) established that the most commonly observed genomic alteration 
was gain of chromosome 20p among the OPL whereas gain of chromosome 8q was 
more common in OSCC. This study has given the first high resolution analysis of whole 
genome in OPLs that represented a significant step towards predicting progression risk 
in early pre-invasive diseases. Likewise, Cha et al. (2011) recently determined the 
genetic alteration of OSCC and the dysplastic transitional area using high resolution 
4x44k oligonucleotide array CGH. They used samples derived from 7 OSCC, which 
included 7 adjacent oral dysplasia and 7 matched margins, normal free of oral mucosa 
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tissues. This study revealed that gain of RNF36 (chromosome 15q21.1) gene was highly 
observed in oral dysplasia compared to OSCC. They also reported that the highest 
frequency of deleted genes in oral dysplasia and OSCC tissues was CKAP2L at 
chromosome 2q13.  
 
To date, Ambatipudi et al. (2011) was the first study to employ high resolution 1 x 105k 
oligonucleotide array CGH to perform genome wide screening for determining the 
chromosomal aberrations associated with poor prognosis. This study revealed that the 
novel chromosomal alterations such as 9p23-24.3 (PTPRD gene) and 5p15.33 (PDCD6 
gene). Moreover, Ambatipudi et al. (2011) compiled a list of genes associated with oral 
cancers based on 25 previous studies. 
 
Since 2002, a numerous number of array CGH studies have been carried out. However, 
some major drawbacks are profounding in these studies. In their studies they employed 
only the non sensitive BAC clone array CGH and low resolution oligonucleotide array 
CGH (4x44k and 1x105k oligonucleotide based array CGH) to screen the whole 
genome chromosomal aberrations in OSCC. In fact these technologies are not capable 
of detecting small genomic alterations in terms of amplification and deletion in the 
genomic regions. On the contrary, the increased density of the ultra dense higher 
resolution aCGH technology will result in 2.1kb median probe spacing which would 
have provided detailed information even at individual exon levels (Przybytkowski et al., 
2011). 
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3.0 Methodology 
3.1 Study Design 
This was a descriptive study to determine the copy number alterations and gene 
pathways that are unique to tongue and cheek SCC. This study was approved by the 
Medical Ethics Committee (MEC), Faculty of Dentistry with the MEC no: 
DFOS1001/0004(P). This was a small part of a large study ["Oral cancer and Pre-cancer 
in Malaysia-Risk factors, prognostic markers, gene expression and impact on quality of 
life"] (DFO0P0306/0018/L) which includes the banking data and tissues.  
 
3.2 Sample selection 
Samples for the study comprised of frozen tissues sections from OSCC patients. For this 
descriptive study, determination of number of samples are based on literature reviews 
and current genome wide screening study on oral cancer using array CGH (Cha et al., 
2011; Sparano et al., 2006; Garnis et al., 2004c; Garnis et al., 2003). Fresh frozen 
tissues (n=20) consisting of 12 tongue and 8 cheek SCC were included in this study and 
were obtained from Malaysian Oral Cancer Database and Tissue Bank System 
(MOCDTBS) coordinated by Oral Cancer Research and Coordinating Center (OCRCC-
UM) and were included in this study. 
 
3.2.1 Demographic characteristics of the samples 
The demographic characteristics of the sample such as age, gender and ethnicwere 
extracted from the MOCDTBS. 
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3.2.2 Sample Criteria  
A)  Inclusion criteria 
1. Oral cancers which are pathologically diagnosed as OSCC. 
2. Primary tumor tissues consisting of epithelial tumor cells with evidence of more 
than 70% of tumor OSCC cells. 
 
B)  Exclusion criteria 
1. Oral cancers which are pathologically diagnosed as other cancer (not OSCC). 
 
 
3.3 Sample Preparation of DNA 
3.3.1Cryosection on frozen tissue 
Frozen tissue specimens were mounted using Optimal Cutting Temperature (OCT) 
compound embedding medium (Leica, Surgipath) and were serially sectioned at -20°C. 
The outer sections of the tissues were H&E stained for histological assessment with the 
help of an experienced pathologist. Tumor percentage was gauged under the microscope 
and macro-dissection was done to obtain ≥ 70% tumor cells for this study. Then, 750 
µm of the section were collected in sterile 1.5ml microcentrifuge tube and subjected for 
DNA extraction. 
 
3.3.2 DNA Extraction 
All tumor tissues for test gDNA samples were isolated by using DNEasy Blood & 
Tissue Kit (Qiagen GmBH Germany) following the manufacturer’s instructions. 750 
µm of the tissue sections were mixed with 1x PBS buffer and then centrifuged in 
5000rpm for 5 minutes. The supernatant were discarded thereafter. Then, 180µl of ATL 
buffer and 20 µl of proteinase K were added and then kept for incubation at 56º C, 
overnight. Later, 200 µl AL buffer was added again and then followed by incubation at 
70°C for 10 minutes. Afterthat, absolute ethanol (200 µl) were added and thereafter all 
the mixtures weretransferred to QIAamp Mini spin for centrifugationat 8000rpm for 1 
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minute. After centrifugation the collection tubes were discarded and new columnswere 
placed into the new collection tubes. To this500 µl AW1 was added and then again 
centrifugedat 8000rpm for 1 minute duration. This process was repeated by changing 
only the buffer with 500 µl AW2. Column was spinned at 13200rpm for 3 minutes in 
order to dry the column membrane. In continuation, 50 µl AE buffer was added into the 
column and then incubated for 5 minutes. Final centrifugation was done at 13200 rpm 
for 3 minutes to collect the elution buffer which contained DNA.  
 
3.3.3 Quantification of DNA measurement 
The quality and quantity of gDNA were verified by Nanodrop ND-2000. DNA 
concentration (ng/µl) and DNA purity (A260/A280) were calculated using the 
spectrophotometer (NanoDrop ND-2000) according to the manufacturer’s instructions. 
 
3.4 Technique to be employed for Array CGH. 
Array CGH was performed using Oxford gene technology according to the method as 
described in manufacturer’s instructions (Agilent Technologies) and also the conditions 
of Srisupundit et al., (2010). Oligonucleotide microarray experiments were performed 
using the Agilent SurePrint G3 Human CGH 1 x 1 M (Agilent Technologies, Santa 
Clara, CA, USA). All the methods were conducted according to manufacturer's protocol 
(version 5.0, June 2007) with minor modification that replaced DNA digestion step to 
defragmentation method. The microarray used for this study was 1 x 1 Million slide 
formats printed using Agilent's 60-mer SurePrint technology which washaving 974,016 
biological features (coding and non-coding sequences represented). The probes cross 
over both the non-coding and coding regions for genome wide-ranging representation. 
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3.4.1 Sample Preparation (Defragmentation Method) for aCGH 
For defragmentation method, total of 500ng of gDNA from each frozen tumor tissue 
(test sample) and commercially gender matched pooled DNA sample (Promega) were 
performed at 98°C for 20 minutes. In this protocol the DNA digestion step was omitted. 
The mixture of both test sample and reference control were transferred to thermomixer 
and then kept for incubation (37°C)overnight.After this duration the mixtures were 
again incubated at 65ºC for 20 minutes to inactive the enzymes. Followed by this, 
agarose gel electrophoresis was run to determine the size of the digested gDNA in the 
length of 200bp-500bp. An amount of 2 µl of the digested genomic DNA (26 µl) was 
taken for 1% agarose gel electrophoresis. The digested products were always taken 
between 200bp-500bp in length. For determining the DNA size, 1 µl DNA Ladder was 
used. Agarose gel electrophoresis was carried out at 110 volts at room temperature. The 
digested DNA was visualized by ethidium bromide staining.  
 
3.4.2 Sample Labellingfor aCGH 
Digested gDNA was fluorescently labelled with cyanine 5-dCTP (test sample) and 
cyanine 3-dCTP (reference control) using a labelling kit (Agilent Genomic DNA 
Labeling Kit PLUS). An amount of 5 µl random primer was added to the digested 
gDNA (24 µl). This was transferred to the thermomixer comfort (Eppendorf, Hamburg, 
Germany) at 95°C for 3 minutes and later moved to ice and incubated for 5 minutes. 
Thereafter, the mixture was mixed with labelling master mix which contained 2 µl of 
nuclease free water, 10 µl 5X Buffer, 5 µl 10X dNTP, 3 µl cyanine 5-dCTP (Test 
sample) or cyanine 3-dCTP (reference control) and 1 µl Exo-Klenow fragment to make 
a total volume of 50 µl. Then the mixture was transferred to thermomixer at 37ºC for 2 
hours followed by 10 minutes incubation at 65°C to inactive the enzyme. 
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3.4.3 Probe Purification for aCGH 
Probe purification was done by using Microcon YM-30 filter column (Millipore, 
Massachusetts, USA). The column was placed into a 1.5 ml microfuge tube and 
centrifuged at 8000rpm for 10 minutes. The supernatant was discarded. Then, 430 µl of 
1X TE (pH 8.0) was mixed with 50 µl of labelled gDNA and loaded all 480 µl mixture 
into the filter and centrifuged for 10 minutes at 8000rpm. Then, the filter was inverted 
into a fresh 1.5 ml microfuge tube and then centrifuged at 8000rpm for 1 minute to 
collect the purified sample. The volume of the purified probe was recommended not 
above 80.5 µl, which was measured using pipetter. Then, 1.5 µl of the purified probe 
was taken to determine the yield and specific activities by using the NanoDrop ND-
2000 UV-VIS Spectrophotometer. 
 
3.4.4 Microarray Hybridization  
An amount of 80.5 µl of Cy5 labelled gDNA mixture and 80.5 µl of Cy3 labelled 
gDNA mixture were mixed together with 50 µl of 1.0 mg/ml Cot-1 DNA, 52 µl of 
Agilent 10X Blocking Agent and 260 µl of Agilent 2X Hybridization Buffer in 1.5 ml 
microcentrifuge tube. The mixture was transferred to thermomixer comfort to incubate 
at 95° C for 3 minutes followed by incubation for 30 minutes at 37º C. Then, the sample 
tubes were centrifuged at 17900 x g for 1 minute to collect the sample at the bottom of 
the tube. 
 
Hybridization sample mixture (490 µl) was slowly dispensed onto the gasket slide well 
in a drag-dispense manner and was fully loaded before placing the Agilent SurePrint G3 
Human CGH 1 x 1 M microarray slide. Then, the microarray slide was placed facing 
down the gasket slide to make sandwich pair. Gently, SureHyb chamber cover was 
placed slowly onto the sandwiched slide and clamped tighten onto the chamber. Next, 
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the assembled chamber was rotated vertically to wet the slides and assessed the mobility 
of the bubbles. The slide chamber was placed in the rotator rack in a hybridization oven 
set to 65° C and rotated at 20rpm for 40 hours.  
 
3.4.5 Washing Preparation for aCGH 
After 40 hours of the hybridization process, Agilent SurePrint G3 Human CGH 1 x 1 M 
microarray slide in a sandwiched pair slide was taken out from the SureHyb chamber 
oven and disassembled in Oligo aCGH Wash buffer 1. Then, the first washing 
procedure was done by placing the slide rack into slide staining dish number 2 and 
washed for 5 minutes. This was followed by the second washing step where the slide 
rack was placed into the pre-warmed glass dish which was filled with Oligo aCGH 
buffer 2 at 37° C for 1 minute. Later, the dish glass was transferred to Acetonitrile and 
was stirred for 1 minute. The slide was scanned immediately to minimize the impact of 
environmental oxidants on signal intensities.  
 
3.4.6 Microarray scanning using Agilent Scanner Control and Feature Extraction 
(FE)  
Slide was assembled into appropriate slide holder in Agilent Microarray Scanner 
(Agilent California) with Agilent Scanner Control software v7.0. Scan region was set to 
61 x 21.6 mm and resolution was set to 2.5µm. Dye channel was set to Red and Green 
where the PTM was set to 100%. Automatic file setting was selected with Prefix 1 
which set to Instrument Serial Number and Prefix 2 was set to Array Barcode. Scanner 
ready signal was appeared after all the setting was completed. Agilent Feature 
Extraction software v9.5 was used to extract microarray CGH data into raw text output 
files. Then, FE quality control report was generated and TIFF images of the hybridized 
array areas was taken.  
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3.5 Analysis 
3.5.1 Data Analysis 
Extracted raw text output data were normalized and converted into cgh files which were 
then uploaded into OGT's CytoSure
TM
 Interpret software and save into a database of all 
pre-processed arrays ready for population analysis to obtain meaningful results. 
 
The CytoSure Interpret software (CBS) package features a circular binary segmentation 
algorithm, where thresholds were set at 0.3 for gains and 0.6 for losses due to a loss of 
chromosomal material. They were takenin the ratio of 2:1 which is the total loss of 
information and the gain is kept as 3:2 to reduce the false positive findings. The calling 
threshold was then set at four ﬂanking probes where Z > 0.016. 
 
For a region to be called as aberrant, it must be present in the both datasets within the 
dye-swap experiment. To complement the CBS algorithm, a second thresholdbased 
method was also applied to the individual probe log2 ratios. Data from the patient 
labelled in Cy5 and in Cy3 is combined as follows: X
2
× Y
2
 = Z (where, X = individual 
probe normalised log2 ratio for Cy5-labelled patient data, Y = individual probe 
normalised log2 ratio for Cy3-labelled patient data).  
 
3.5.2 Population analysis 
The population analysis is a feature in Cytosure software that provides calculation and 
graphing of aberration frequencies from groups derived from the saved database. Hence, 
in this study, all tongue and cheek SCC array CGH files were saved into the database 
which was labelled as cheek and tongue, respectively and were taken for population 
analysis to obtain the unique copy number alterations (CNAs) among these two distinct 
groups. All CNAs that were found common in both tongue and check SCC were 
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excluded. As a further filter, only CNAs within genic regions were used for further 
interpretation. 
 
3.5.3 Pathway Analysis 
The set of genes of obtained from Cytosure software included the amplified and deleted 
genes in tongue and cheek SCC, respectively were uploaded into MetaCore™ analytical 
suite version 4.5 (GeneGo, Inc., St. Joseph, MI) and the analysis was conducted in 
accordance with the application manual. List of amplified and deleted genes were 
analyzed for pathway analysis in MetaCore
TM
 and the results were ranked by p-value. 
Only significant pathway with FDR< 0.05 was included in this study.  
 
For determining the representation of pathways dictated by an input list, MetaCore 
software applies a hyper geometric distribution statistics (A standard statistic used to 
compare populations). In the present study, the “p value” was compared to the 
population as represented by the data to a selected ontology or network algorithm. Like 
any other statistics the “p value” or statistical significance in Metacore software was a 
measure of the likelihood that an event would happen purely by chance. The 
hypergeometric statistic in particular takes into account the number of objects in the 
dataset, the number of objects in the intersecting map/network (in the enrichment 
ontology used) and the number of objects in the entire database. This assessment would 
therefore return the significance level that tells us the likelihood that intersects between 
the dataset and a particular map/network, purely obtained by chance. 
 
Athough the hypergeometric statistic calculation could be the major drawbacks of this 
software, since the outcomes are mainly derived by chance but Metacore is the only tool 
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that has the largest collection of pathway maps to be able to do this type of analysis and 
that the maps are manually constructed based on high quality experiments.  
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4.0 Result 
4.1 Demographic characteristic of the study samples 
The mean age of patients whose tumor samples were used for the study was 
54.85±16.13 years with 7 males and 13 females. From the total samples, about 65% of 
the cases were in pathological stage III or IV. The details for each case are as in table 
4.1. 
 
Table 4.1: Demographic characteristics of study samples. 
Case 
Number 
Age 
(years) 
Gender Ethnic Site Differentiation pTNM  
1 43 M Others Cheek WELL III  
2 70 F Indian Cheek MOD IV  
3 59 M Indian Tongue WELL I  
4 53 F Others Tongue WELL IV  
5 29 F Malay Tongue WELL III  
6 80 M Chinese Tongue MOD II  
7 74 F Indian Cheek WELL III  
8 42 F Malay Tongue WELL IV  
9 67 M Malay Cheek WELL IV  
10 78 F Indian Cheek MOD IV  
11 57 M Others Cheek MOD IV  
12 49 F Malay Tongue MOD IV  
13 26 F Indian Tongue WELL I  
14 47 M Malay Tongue WELL II  
15 30 M Malay Tongue MOD IV  
16 52 F Indian Tongue MOD IV  
17 61 F Indian Cheek MOD II  
18 75 F Indian Cheek MOD IV  
19 49 F Indian Tongue WELL I  
20 56 F Indian Tongue MOD I  
Abberration: M=Male; F=Female; WELL=Well Differentiation; MOD=Moderate 
Differentiation 
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4.2 Chromosomal alterations (aberrations) detected using array CGH and genes 
involved 
All 20 cases of OSCC used in this study showed chromosomal aberrations. Summaries 
of chromosomal gains and losses by array CGH on tongue SCC analysis are illustrated 
in tables 4.2 and 4.3 respectively. Tables 4.4 and 4.5 shows summary of losses and 
gains of chromosomal segments observed in cheek SCC, respectively. Comparison of 
chromosomal aberrations of tongue SCC and cheek SCC using Cytosure software 
showed chromosomal aberrations in 210 genes for tongue SCC. These included 187 
amplified gene and 23 deleted genes. In contrast to tongue SCC, there were 
chromosomal aberrations of 71 genes for cheek SCC which included 23 amplified genes 
and 48 deleted genes. The mean number of chromosomal aberrations per tumor for 
tongue SCC (22.75±26.58) was higher than for cheek SCC (8.63±11.89). 
 
4.2.1 Chromosomal aberrations detected genes involved in tongue SCC 
Table 4.2 and 4.3 lists the 187 amplified and 23 deleted genes identified from tongue 
SCC, respectively. In this study, there were five most common amplified regions which 
were 8q24.22 (33.33%), 8q24.3 (33.33%), 11q13.2 (33.33%), 12q13.13 (33.33%), 
14q32.33 (33.33%) whereas the most common deleted regions were 2q21.1 (16.67%) 
and 6q21 (16.67%). Genes which were amplified at chromosomal regions 8q24.22 
contained WISP1 and gene discovered at 8q24.3 was DENND3. For region 11q13.2, the 
amplified gene was CCDC87. Amplified gene at region 12q13.13 was HOXC13 while 
at 14q32.33, the gene involved was CDCA4. For the deleted genes, TUBA3D and 
LACE1 were found at chromosomal regionsat 2q21.1 and 6q21, respectively. 
 
 
 
63 
 
Table 4.2: Details of the amplified regions for each chromosome in 12 tongue SCC. 
Chromosome 
(Cytoband) 
Position 
Start (bp*) 
Position 
Stop(bp*) 
Size 
(kb*) 
Frequency 
No 
Gene Name 
1p36.13 17173727 17178735 5.008 1 MFAP2 
1p36.21 13786019 13816638 30.619 1 PDPN 
1q32.2 207854989 207892155 37.166 1 LAMB3 
1q32.2 207933242 207974704 41.462 1 HSD11B1 
1q21.1 144271009 144279871 8.862 1 ANKRD35 
2q31.1 176697610 176726177 28.567 1 HOXD3 
2q31.1 171353649 171396655 43.006 1 GAD1 
3p21.31 45777623 45784991 7.368 1 SLC6A20 
3q22.3 139549846 139606863 57.017 1 MRAS 
3q23 144320888 144324458 3.57 2 CHST2 
3q24 150191793 150227721 35.928 2 GYG1 
3q25.2 156279994 156384067 104.073 2 MME 
4p16.3 2814573 2901366 86.793 2 ADD1 
4p15.32 17189465 17218539 29.074 2 LAP3 
4p15.2 26207471 26365538 158.067 2 TBC1D19 
4p14 38723098 38804575 81.477 1 KLHL5 
4p14 40953629 40965137 11.508 1 UCHL1 
5q23.3 131846712 131854231 7.519 3 IRF1 
5q32 149656691 149662626 5.935 1 ARSI 
6p24.1 11824981 11914856 89.875 1 C6orf105 
6p12.3 49626351 49637536 11.185 1 C6orf141 
6q25.3 160143191 160161671 18.48 1 PNLDC1 
6p21.33 31538937 31541421 2.484 1 HCP5 
6p21.31 35179083 35217098 38.015 2 TCP11 
6p21.31 35788157 35803837 15.68 2 FKBP5 
6p21.31 36437239 36476426 39.187 2 ETV7 
6p21.1 43158819 43237417 78.598 2 PTK7 
6p22.1 26389604 26393724 4.12 1 HIST1H4H 
6p22.1 26473707 26561548 87.841 1 BTN3A2 
6p22.1 26511387 26561548 50.161 1 BTN3A2 
6p22.1 26549309 26561548 12.239 1 BTN3A3 
6p22.1 29071557 29080878 9.321 1 ZNF311 
6p22.1 29627716 29708258 80.542 1 GABBR1 
6p21.33 31204971 31215767 10.796 1 PSORS1C1 
6q25.3 160141234 160161399 20.165 1 PNLDC1 
7p15.3 24704967 24763847 58.88 1 DFNA5 
7p15.1 29926627 29995512 68.885 1 SCRN1 
7p13 45006049 45082131 76.082 1 CCM2 
7p11.2 55050689 55240708 190.019 2 EGFR 
7p11.2 56099397 56115745 16.348 1 SUMF2 
7q11.23 72621076 72630946 9.87 3 TBL2 
7q22.1 98810308 98830216 19.908 1 ARPC1B 
7q36.1 150180531 150189198 8.667 1 ABP1 
7p15.2 27095898 27149791 53.893 1 HOXA1, HOXA3 
8p21.2 27223463 27313957 90.494 1 PTK2B 
8q22.3 104104531 104153424 48.893 1 ATP6V1C1 
8q22.3 104224163 104256121 31.958 1 BAALC 
8p21.3 22355303 22366416 11.113 1 PPP3CC 
64 
 
8q24.11 118918056 119198326 280.27 1 EXT1 
8q24.13 126055333 126060447 5.114 2 ZNF572 
8q24.13 126196625 126445872 249.247 2 NSMCE2 
8q24.22 134273951 134310617 36.666 4 WISP1 
8q24.3 142207959 142274555 66.596 4 DENND3 
9q34.13 134664598 134743659 79.061 1 C9orf98 
9q22.33 98039129 98104004 64.875 1 HSD17B3 
9q32 115278405 115397080 118.675 2 RGS3 
9q33.1 116831323 116920031 88.708 1 TNC 
9q34.3 136655451 136674300 18.849 1 COL5A1 
9q34.3 137593925 137598618 4.693 1 PAEP 
10q24.2 99407997 99510452 102.455 1 ZFYVE27 
10q26.3 134906557 134940323 33.766 3 ADAM8 
10p12.33 17673021 17699336 26.315 1 PTPLA 
10p12.33 17900075 17992777 92.702 1 MRC1L1 
10p12.1 25189493 25281202 91.709 1 PRTFDC1 
10p11.22 33231119 33287171 56.052 1 ITGB1 
10q11.21 44778909 44804392 25.483 2 RASSF4 
10q21.2 62317787 62431144 113.357 1 RHOBTB1 
10q21.3 69536826 69640844 104.018 1 MYPN 
10q21.3 69730465 69762648 32.183 1 PBLD 
10q24.2 99324084 99333368 9.284 1 ANKRD2 
10q25.1 106103709 106106235 2.526 2 CCDC147 
10q25.2 114128606 114177763 49.157 1 ACSL5 
10q26.11 120779322 120780972 1.65 1 NANOS1 
10q26.12 121478692 121578038 99.346 1 INPP5F 
10q26.13 124215266 124264200 48.934 2 HTRA1 
10q26.13 124743238 124758245 15.007 1 IKZF5 
11p15.5 278928 285642 6.714 1 ATHL1 
11q12.3 62973282 63015147 41.865 2 HRASLS5 
11P11.2 47330263 47427282 97.019 1,2 SPI1, RAPSN 
11p15.5 1898505 1916357 17.852 2 TNNT3 
11p15.3 12092713 12241401 148.688 2 MICAL2 
11p11.2 45637655 45643584 5.929 1 CHST1 
11p11.2 47638037 47692751 54.714 1 AGBL2 
11q12.1 57079389 57138518 59.129 1 UBE2L6, SERPING1 
11q12.2 60438242 60447436 9.194 3 TMEM109 
11q12.3 63064947 63087387 22.44 3 RARRES3, HRASLS2 
11q13.2 66114705 66117058 2.353 4 CCDC87 
11q13.4 73730096 73787027 56.931 1 PGM2L1 
11q13.5 76980583 76998194 17.611 2 AQP11 
11q14.1 77404751 77411989 7.238 2 KCTD14 
11q14.2 86336369 86344063 7.694 2 FZD4 
11q14.2 86426396 86709231 282.835 1 TMEM135 
11q14.2 87666768 87709775 43.007 1 CTSC 
11q22.2 101797089 102399026 601.937 2 MMP7, MMP10, 
MMP1, MMP3, 
MMP13 
11q23.3 117570358 117600835 30.477 1 AMICA1 
11q23.3 118794199 118800044 5.845 1 THY1 
12q21.31 83954316 84160801 206.485 1 LRRIQ1 
12p13.31 6431637 6440583 8.946 3 TAPBPL 
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12p13.31 6519363 6535496 16.133 3 IFFO1 
12p13.31 6751897 6757816 5.919 3 LAG3 
12p13.31 6894036 6902891 8.855 3 ENO2 
12p13.31 6974939 7046058 71.119 1 C1S 
12p13.31 7167563 7172746 5.183 1 RBP5 
12p11.21 32152836 32223652 70.816 1 BICD1 
12q13.12 47675392 47679321 3.929 1 DDN 
12q13.12 48738561 48763522 24.961 1 ACCN2 
12q13.13 51058305 51065637 7.332 1 KRT84 
12q13.13 52619392 52626446 7.054 4 HOXC13 
12q13.13 52972184 52975801 3.617 1 NFE2 
12q13.2 54515588 54522936 7.348 1 MMP19 
12q13.3 55021709 55040075 18.366 1 STAT2 
12q23.3 103979457 104002318 22.861 1 ALDH1L2 
12q23.3 107214336 107257185 42.849 1 CMKLR1 
12q24.13 111838770 111853973 15.203 1 OAS1, OAS2 
12q24.13 112320466 112359994 39.528 1 SDS, SDSL 
13q21.2 59282895 59290208 7.313 2 DIAPH3 
13q32.3 99413301 99436918 23.617 2 ZIC5, ZIC2 
14q32.2 99870220 99912155 41.935 1 WARS 
14q32.13 93713859 93810227 96.368 1 PPP4R4 
14q32.13 94148362 94159975 11.613 1 SERPINA3 
14q22.2 54295792 54325384 29.592 3 SAMD4A 
14q31.1 80754809 80931555 176.746 1 STON2 
14q31.3 85073759 85162748 88.989 1 FLRT2 
14q31.3 87472049 87529642 57.593 1 GALC 
14q32.13 93471727 93493383 21.656 1 ASB2 
14q32.13 93617425 93652468 35.043 1 IFI27L1, IFI27 
14q32.31 101298118 101462533 164.415 2 PPP2R5C 
14q32.33 104547601 104558273 10.672 4 CDCA4 
15q24.1 72620931 72676274 55.343 1 ARID3B 
15q25.2 82949282 82967115 17.833 1 ZSCAN2 
15q25.2-
15q25.3 
82999397 83002792 3.395 1 NMB 
15q26.2 92612534 92822582 210.048 1 MCTP2 
15q11.2 18887165 18970887 83.722 3 HERC2P2 
16q24.3 88348597 88410356 61.759 1 FANCA 
16p13.13 11991779 12000539 8.76 1 RUNDC2A 
16q12.1 49337161 49345341 8.18 1 CYLD 
16q22.1 66525882 66528243 2.361 2 PSMB10 
16q22.1 66579726 66590793 11.067 2 DPEP2 
16q24.1 85158357 85160018 1.661 1 FOXL1 
17q21.31 40184574 40184919 0.345 1 DBF4B 
17q25.1 71452224 71486882 34.658 1 ACOX1 
17p11.2 18864731 18869144 4.413 1 GRAP 
17p11.2 24048981 24053357 4.376 1 SUPT6H 
17q21.31 39497185 39499525 2.34 1 LSM12 
17q21.32 43480047 43488533 8.486 1 NFE2L1 
17q21.32 43984403 44006794 22.391 1 HOXB3 
17q23.1 50829759 50854316 24.557 1 MMD 
17q23.2 53404297 53420590 16.293 1 VEZF1 
17q23.2 54587515 54634550 47.035 1 PRR11 
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18q11.2 18006926 18035637 28.711 3 GATA6 
18q11.2 19541601 19759913 218.312 3 LAMA3 
18q12.1 27337511 27380493 42.982 1 DSG2 
18q21.1 45360066 45364337 4.271 3 LIPG 
19q13.42 60335823 60352240 16.417 1 TNNT1 
19q13.42 60688438 60690717 2.279 1 NAT14 
20q13.12 44070959 44078427 7.468 2 MMP9 
20q13.12 43888615 43895771 7.156 1 TNNC2 
20q11.22 33593171 33608629 15.458 1 ERGIC3 
20q11.21 30820954 30860463 39.509 1 DNMT3B 
20q11.22 33222904 33228740 5.836 1 PROCR 
20q11.23 34954902 35013513 58.611 1 SAMHD1 
20q11.23 36190424 36226992 36.568 1 TGM2 
20q13.12 42538389 42556442 18.053 1 TTPAL 
20q13.12 43185486 43186512 1.026 1 WFDC12 
20q13.12 43185564 43238568 53.004 1 PI3 
20q13.12 43875211 43878987 3.776 1 UBE2C 
20q13.13 47101835 47146360 44.525 1 CSE1L 
20q13.13 47289194 47328156 38.962 1 ZNFX1 
20q13.2 52529429 52539281 9.852 2 DOK5 
20q13.32 55612686 55719537 106.851 1 ZBP1, PMEPA1 
20q13.32 56468502 56523193 54.691 1 APCDD1L 
21q22.12 35082078 35098101 16.023 1 RUNX1 
21q22.11 33723598 33728314 4.716 2 IFNGR2 
21q11.2-
21q21.1 
15263756 15355324 91.568 1 NRIP1 
bp*=base pair; kb*=kilo base pair 
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Table 4.3: Details of the deleted regions for each chromosome in 12 tongue SCC 
cases. 
Chromosome 
(Cytoband) 
Position 
Start (bp*) 
Position 
Stop(bp*) 
Size 
(kb*) 
Frequency 
No 
Gene Name 
2p23.2 28235311 28242770 7.459 1 BRE 
2p23.2 29671435 29678404 6.969 1 ALK 
2q21.1 131950134 131956930 6.796 2 TUBA3D 
2q33.3 205164282 205440801 276.519 1 PARD3B 
2q34 211243669 211251963 8.294 1 CPS1 
2q34 214582908 214586990 4.082 1 SPAG16 
4q11 52612324 52658188 45.864 1 SPATA18 
4q12 54020883 54152305 131.422 1 LNX1 
4q12 56731115 56733122 2.007 1 KIAA1211 
6q21 108828360 108832065 3.705 2 LACE1 
6q26 162979182 162994871 15.689 1 PARK2 
 7q32.1 126267469 126282441 14.972 1 GRM8 
9p24.1 6231654 6247861 16.207 1 IL33 
9p22.3 6231654 6247861 16.207 1 c9orf93 
9p22.2 17568481 17782593 214.112 1 SH3GL2 
10q25.3 116929774 116963934 34.16 1 ATRNL1 
11p15.1 20917601 20944649 27.048 1 NELL1 
18q12.1 30007775 30019752 11.977 1 NOL4 
19p12 20595355 20635991 40.636 1 ZNF626 
19p12 20897856 20924883 27.027 1 ZNF85 
20p12.2 9467146 9767439 300.293 1 PAK7 
20p12.1 13777292 13918422 141.13 1 SEL1L2 
22q11.1 15822604 15868880 46.276 1 GAB4 
bp*=base pair; kb*=kilo base pair 
 
4.2.2 Chromosomal aberrations and detected genes involved in cheek SCC 
Table 4.4 and 4.5 lists the amplified and deleted genes identified from cheek SCC, 
respectively. The genome wide information obtained from array CGH on cheek SCC 
showed amplification of 22q12.3 as the most frequently observed chromosomal 
aberration (25%) and the gene identified in this region was APOL1. On the contrary, the 
most deleted regions were identified in the chromosome 2q22.1 (25%), 7q35 (25%) and 
19q13.33 (25%) which mapped with LRP1B, CNTNAP2 and FUT2 genes, respectively. 
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Table 4.4: Details of the amplified regions for each chromosome in 8 cheek SCC 
cases. 
Chromosome 
(Cytoband) 
Position Start 
(bp*) 
Position 
Stop(bp*) 
Size 
(kb*) 
Frequency 
No 
Gene Name 
1q25.1 173300562 173379842 79.28 1 TNN 
1q25.2 177335027 177335306 0.279 1 ABL2 
2p23.1 30313491 30348049 34.558 1 LBH 
3p25.2 12950575 12983916 33.341 1 IQSEC1 
3p22.1 42701984 42717935 15.951 1 KBTBD5, HHATL 
3q21.1 123741593 123776009 34.416 1 PARP9, DTX3L 
4q11 52612495 52628952 16.457 1 SPATA18 
6q21 112654596 112662700 8.104 1 LAMA4 
7p14.3 32964292 33012655 48.363 1 FKBP9 
7p14.1 41695169 41709208 14.039 1 INHBA 
7q32.1 128190946 128198375 7.789 1 CALU 
8p12 31759525 31766348 6.823 1 NRG1 
9p13.3 35663862 35671065 7.203 1 CA9 
9p13.3 35063878 35069996 6.118 1 FANCG 
9p13.3 35087688 35093116 5.428 1 STOML2 
9p13.3 34979730 34988341 8.611 1 DNAJB5 
9p13.2 38382700 38388633 5.933 1 ALDH1B1 
9q21.13 73372022 73564287 192.265 1 TMEM2 
19p13.3 6615584 6621581 5.997 1 TNFSF14 
19q13.33 55084766 55092186 7.42 1 IL4I1 
22q12.3 34978564 34988898 10.334 2 APOL1 
bp*=base pair; kb*=kilo base pair 
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Table 4.5: Details of the deleted regions for each chromosome in 8 cheek SCC 
cases. 
Chromosome 
(Cytoband) 
Position 
Start (bp*) 
Position 
Stop(bp*) 
Size 
(kb*) 
Frequency 
No 
Gene Name 
1p22.3 86159237 86175251 16.014 1 COL24A1 
2q22.1 131950134 131956930 6.796 2 LRP1B 
3p26.3 213534 423608 210.074 1 CHL1 
3p26.3 1108466 1418836 310.37 1 CNTN6 
3p26.3-
3p26.2 
2255213 3070579 815.366 1 CNTN4 
3p25.3 9666093 9718597 52.504 1 MTMR14 
3p25.3 9720475 9746339 25.864 1 CPNE9 
3p25.3 9871336 9907828 36.492 1 CIDEC 
3p25.3 11009390 11055504 46.114 1 SLC6A1 
3p25.2 12304193 12449328 145.135 1 PPARG 
3p25.2 12813148 12850999 37.851 1 TMEM40 
3p25.1 14691659 14788696 97.037 1 C3orf20 
3p24.1 30623156 30867024 243.868 1 TGFBR2 
3p24.1 30623156 30867024 243.868 1 GADL1 
3p23 32255093 32385426 130.333 1 CMTM8 
3p22.3 36397255 36562637 165.382 1 STAC 
3p22.3 37468570 37835081 366.511 1 ITGA9 
3p22.2 38470768 38509347 38.579 1 ACVR2B 
3p22.1 41512795 41552303 39.508 1 ULK4 
3p21.31 46452680 46481467 28.787 1 LTF 
3p21.31 46728608 46734352 5.744 1 TSP50 
3p21.31 49566923 49683032 116.109 1 BSN 
3p21.31 49696399 49701098 4.699 1 MST1 
3p21.2 52255225 52259610 4.385 1 PPM1M 
3p14.3 54518914 54660981 142.067 1 CACNA2D3 
3p14.2 62330439 62334204 3.765 1 FEZF2 
3p14.1 63971362 63984450 13.088 1 PSMD6 
3p14.1 69871009 70098183 227.174 1 MITF 
3p13 73512066 73756515 244.449 1 PDZRN3 
3p12.1 87069733 87122868 53.135 1 VGLL3 
3p11.2 87391526 87408424 16.898 1 POU1F1 
7q35 145776903 145923085 146.182 2 CNTNAP2 
8p23.1 10501415 10606095 104.68 1 RP1L1 
8p23.1 10618655 10625437 6.782 1 SOX7 
8p21.3 23299350 23367704 68.354 1 ENTPD4 
8p21.1 27492216 27527997 35.781 1 CLU 
8p12 38153461 38189731 36.27 1 BAG4 
10q11.22 46413545 46420541 6.996 1 GPRIN2 
10q11.22 56841264 56851024 9.76 1 PPYR1 
10q21.3 67856106 67862075 5.969 1 CTNNA3 
12p12.1 25552267 25558944 6.677 1 IFLTD1 
14q31.1 79176042 79183210 7.168 1 NRXN3 
15q13.1 25856742 25861802 5.06 1 OCA2 
16p13.2 7336826 7343082 6.256 1 A2BP1 
16p12.1 48082088 48371710 289.622 1 ZNF423 
18p11.23 7962551 7967038 4.487 1 PTPRM 
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19q13.33 53892650 53900934 8.284 2 FUT2 
20q13.12 45214224 45220304 6.08 1 EYA2 
bp*=base pair; kb*=kilo base pair 
 
4.3 Significant signaling pathways analysis from data sets of chromosomal 
aberrations in tongue and cheek SCC 
 
 
To elucidate which biological pathways are affected between tongue and cheek SCC, 
the amplified and deleted genes were subjected to pathway analysis using MetaCore 
Software. Summaries of the significant pathways (p<0.05) identified from amplified 
and deleted genes from tongue SCC are illustrated in tables 4.6 and 4.7 respectively. 
The pathway analysis revealed 40 and 17 significant pathways affected by amplified 
and deleted genes, respectively in tongue SCC. Pathway analysis of the amplified and 
deleted genes that were found in cheek SCC yielded 20 and 10 significant pathways 
(p<0.05), respectively and are illustrated in table 4.8 and 4.9. 
 
4.3.1 Significant signaling pathways of tongue SCC 
In depth biological analysis by MetaCore
TM
 Software revealed that the most significant 
pathway involved in the amplified gene was cell adhesion ECM remodeling pathway. 
This study determined that 11/187 of amplified genes were member of cell adhesion 
ECM remodeling pathway. The amplified genes involved in this pathway include 
EGFR, ITGB1, LAMA3, LAMB3, MMP1, MMP10, MMP2, MMP13, MMP3, MMP7, 
MMP9. On the other hand, the most significant pathway involved in the deleted genes 
of tongue SCC was proteolysis (Role of Parkin) in Ubiquitin-Proteasomal Pathway. The 
deleted genes involved in this pathway were PARK2 and TUBA3D. 
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Table 4.6: Significant biological pathway associated with amplified genes from 
tongue SCC. 
 
No Pathway P value Gene(s) 
1 Cell adhesion ECM remodeling 2.942e-
10 
EGFR, ITGB1, LAMA3, 
LAMB3, MMP1, MMP10, 
MME (MMP12), MMP13, 
MMP3, MMP7, MMP9 
2 Immune response Antiviral 
actions of Interferons 
3.888e-6 IFNGR2, IRF1, OAS1, OAS2, 
STAT2, WARS 
3 Immune response Histamine H1 
receptor signaling in immune 
response 
4.360e-5 MMP1, MMP13, MMP3, 
MMP9, PPP3CC 
4 Cell adhesion Cell-matrix 
glycoconjugates 
2.568e-4 ITGB1, MMP1, MMP3, 
MMP9, TNC 
5 Regulation of lipid metabolism 
Regulation of fatty acid synthase 
activity in hepatocytes 
4.786e-4 ADD1 
6 Development Role of IL-8 in 
angiogenesis 
1.304e-3 EGFR, ADD1, ARPC1B 
7 Development Angiotensin 
signaling via STATs 
2.268e-3 PPP3CC, PTK2B,STAT2 
8 Immune response Oncostatin M 
signaling via MAPK in mouse 
cells 
2.941e-3 MMP1, MMP13, MMP3 
9 Immune response Oncostatin M 
signaling via MAPK in human 
cells 
3.450e-3 MMP1, MMP13, MMP3 
10 Regulation of lipid metabolism 
Regulation of lipid metabolism 
via LXR, NF-Y and SREBP 
3.724e-3 ADD1 
11 Transcription Androgen 
Receptor nuclear signaling 
6.011e-3 EGFR, FZD4, PTK2B 
12 Immune response Oncostatin M 
signaling via JAK-Stat in mouse 
cells 
9.490e-3 MMP1, SERPINA3 
13 Immune response Oncostatin M 
signaling via JAK-Stat in human 
cells 
1.166e-2 MMP1, SERPINA3 
14 Cytoskeleton remodeling TGF, 
WNT and cytoskeletal 
remodeling 
1.327e-2 FZD4, MMP13, MMP7, 
SERPING1, MMP1, ARPC1B 
15 Immune response IL-17 
signaling pathways 
1.328e-2 MMP1, MMP3, MMP9 
16 Development Regulation of 
epithelial-to-mesenchymal 
transition (EMT) 
1.579e-2 EGFR, FZD4, MMP9 
17 Immune response IFN alpha/beta 
signaling pathway 
1.658e-2 IRF1, STAT2 
18 Glycolysis and gluconeogenesis 
p.3 / Human version 
1.658e-2 ENO2 
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19 Glycolysis and gluconeogenesis 
p.3 
1.658e-2 ENO2 
20 Transport RAB5A regulation 
pathway 
1.793e-2 EGFR,INPP5F 
21 Transcription Transcription 
regulation of aminoacid 
metabolism 
1.793e-2 NFE2, NFE2L1 
22 Cytoskeleton remodeling 
Reverse signaling by ephrin B 
2.692e-2 LAP3, RGS3, ARPC1B 
23 Beta-alanine metabolism/ 
Rodent version 
2.856e-2 ABP1, GAD1 
24 Development Transcription 
regulation of granulocyte 
development 
2.856e-2 RUNX1, SPI1 
25 Development Angiotensin 
activation of ERK 
3.025e-2 EGFR, PTK2B 
26 G-protein signaling G-Protein 
alpha-q signaling cascades 
3.197e-2 PTK2B, RGS3 
27 Immune response CXCR4 
signaling via second messenger 
3.197e-2 LAP3, PTK2B 
28 Fatty Acid Omega Oxidation 3.197e-2 ACOX1, ACSL5 
29 Chemotaxis CXCR4 signaling 
pathway 
3.197e-2 LAP3, PTK2B 
30 Keratan sulfate metabolism p.1 3.373e-2 CHST1, CHST2 
31 Cell adhesion Plasmin signaling 3.373e-2 MMP1, MMP13, SERPING1 
32 Beta-alanine metabolism 3.373e-2 ABP1, GAD1 
33 Regulation of lipid metabolism 
Insulin regulation of fatty acid 
methabolism 
3.617e-2 ADD1 
34 Regulation of metabolism Bile 
acids regulation of glucose and 
lipid metabolism via FXR 
3.736e-2 ADD1 
35 HIV-1 signaling via CCR5 in 
macrophages and T lymphocytes 
4.113e-2 PPP3CC,  PTK2B 
36 Keratan sulfate metabolism p.2 4.113e-2 CHST1, CHST2 
37 Translation Non-genomic (rapid) 
action of Androgen Receptor 
4.307e-2 EGFR, FZD4 
38 Apoptosis and survival BAD 
phosphorylation 
4.704e-2 EGFR, PPP3CC 
39 Development ACM2 and ACM4 
activation of ERK 
4.908e-2 EGFR, PTK2B 
40 Cell adhesion Chemokines and 
adhesion 
4.973e-2 ARPC1B, ITGB1, LAMA3, 
MMP1, MMP13 
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Table 4.7: Significant biological pathway associated with deleted genes from 
tongue SCC. 
No Pathways  P value Gene(s) 
1 Proteolysis Role of Parkin in the 
Ubiquitin-Proteasomal Pathway 
1.704e-4 PARK2, TUBA3D 
2 UMP biosynthesis 1.693e-2 CPS1 
3 Proteolysis Putative ubiquitin pathway 1.945e-2 PARK2 
4 Cytoskeleton remodeling Role of 
PDGFs in cell migration 
2.029e-2 PAK7 
5 Cytoskeleton remodeling 
Neurofilaments 
2.112e-2 TUBA3D 
6 Neurophysiological process Role of 
CDK5 in presynaptic signaling 
2.363e-2 SH3GL2 
7 Cell adhesion Gap junctions 2.530e-2 TUBA3D 
8 Cytoskeleton remodeling Reverse 
signaling by ephrin B 
2.614e-2 TUBA3D 
9 Cell cycle Role of Nek in cell cycle 
regulation 
2.697e-2 TUBA3D 
10 Apoptosis and survival Granzyme B 
signaling 
2.697e-2 TUBA3D 
11 Cell cycle Spindle assembly and 
chromosome separation 
2.780e-2 TUBA3D 
12 Nitrogen metabolism 2.947e-2 CPS1 
13 Nitrogen metabolism/ Rodent version 3.030e-2 - 
14 Cytoskeleton remodeling Keratin 
filaments 
3.030e-2 TUBA3D 
15 Aldosterone biosynthesis and 
metabolism 
3.444e-2 CPS1 
16 Apoptosis and survival TNFR1 
signaling pathway 
3.610e-2 BRE 
17 Apoptosis and survival FAS signaling 
cascades 
3.610e-2 BRE 
 
4.3.2 Significant signaling pathways of cheek SCC 
In cheek SCC, results obtained with MetaCore software showed cytoskeleton 
remodeling (Role of Activin A) in cytoskeleton remodeling and cadherin mediated cell 
adhesion pathway were the top biological pathway associated with amplified and 
deleted genes, respectively. It was found that 2 of the 48 deleted genes were members of 
the cadherin mediated cell adhesion pathway, including CTNNA3 and PTPRM genes. 
In contrast, the identified amplified gene which falls in the cytoskeleton remodeling 
(Role of Activin A) in cytoskeleton remodeling pathway was INHBA. 
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Table 4.8: Significant biological pathway associated with amplified genes from 
cheek SCC. 
No Pathways  P value Gene(s) 
1 Cytoskeleton remodeling Role of Activin A in 
cytoskeleton remodeling 
1.933e-2 INHBA 
2 Atherosclerosis Role of ZNF202 in regulation 
of expression of genes involved in 
Atherosclerosis 
2.028e-2 APOL1 
3 Cholesterol and Sphingolipids transport / 
Recycling to plasma membrane in lung 
(normal and CF) 
2.220e-2 APOL1 
4 Apoptosis and survival Apoptotic Activin A 
signaling 
2.411e-2 INHBA 
5 Histamine metabolism 3.076e-2 ALDH1B1 
6 Signal transduction Activin A signaling 
regulation 
3.171e-2 INHBA 
7 Apoptosis and survival Role of CDK5 in 
neuronal death and survival 
3.266e-2 NRG1 
8 Ascorbate metabolism / Rodent version 3.266e-2 ALDH1B1 
9 Nitrogen metabolism 3.361e-2 CA9 
10 Nitrogen metabolism/ Rodent version 3.455e-2 CA9 
11 Development ERBB-family signaling 3.738e-2 NRG1 
12 Development Role of Activin A in cell 
differentiation and proliferation 
3.833e-2 INHBA 
13 Translation Non-genomic (rapid) action of 
Androgen Receptor 
3.833e-2 NRG1 
14 Apoptosis and survival Lymphotoxin-beta 
receptor signaling 
3.927e-2 TNFSF14 
15 Apoptosis and survival Apoptotic TNF-family 
pathways 
4.021e-2 TNFSF14 
16 Development Ligand-independent activation 
of ESR1 and ESR2 
4.209e-2 NRG1 
17 Role of alpha-6/beta-4 integrins in carcinoma 
progression 
4.302e-2 NRG1 
18 Niacin-HDL metabolism 4.490e-2 APOL1 
19 Pyruvate metabolism 4.677e-2 ALDH1B1 
20 Cell adhesion ECM remodeling 4.957e-2 LAMA4 
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Table 4.9: Significant biological pathway associated with deleted genes from cheek 
SCC. 
No Pathways  P value Gene(s) 
1 Cell adhesion Cadherin-mediated cell 
adhesion 
8.569e-4 CTNNA3, PTPRM 
2 Cell adhesion Role of CDK5 in cell adhesion 1.525e-2 CTNNA3 
3 Regulation of lipid metabolism Regulation 
of fatty acid synthesis: NLTP and EHHADH 
3.028e-2 PPARG 
4 Development TGF-beta-induction of EMT 
via ROS 
3.193e-2 TGFBR2 
5 Cytoskeleton remodeling Role of Activin A 
in cytoskeleton remodeling 
3.359e-2 ACVR2B 
6 Cell adhesion Endothelial cell contacts by 
non-junctional mechanisms 
4.018e-2 CTNNA3 
7 Apoptosis and survival Apoptotic Activin A 
signaling 
4.182e-2 ACVR2B 
8 Cell adhesion Endothelial cell contacts by 
junctional mechanisms 
4.346e-2 CTNNA3 
9 Possible pathway of TGF-beta 1-dependent 
inhibition of CFTR expression 
4.509e-2 TGFBR2 
10 Regulation of lipid metabolism RXR-
dependent regulation of lipid metabolism via 
PPAR, RAR and VDR 
4.999e-2 PPARG 
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5.0 Discussion 
This study was performed to determine the chromosomal aberrations (alterations) in 
tongue and cheek SCC using array CGH technology and to identify genes that act in 
similar pathway. The genes which interact together during oncogenesis that are thought 
to link the genes in various copy number aberrations via pathway analysis have been 
identified in order to strengthen this study. 
 
To the best of our knowledge, this is the first study using an ultra dense array CGH for 
the discovery of cancer genes on the subsites of OSCC (tongue and cheek) in which 
ultra high (2.1kb) resolution definition of DNA copy number aberrations were 
generated from frozen tissue sections. Strength ofour study is that the chromosomal 
aberrations and pathways involved in oral carcinoma genesis were analyzed separately 
based on the specific subsites within the oral cavity. Moreover, this study also managed 
to show the micro-copy number aberrations (CNAs), defined as < 1Mb in genomic 
length. This demonstrated the sensitivity of the ultra-dense array CGH on gDNA of 
frozen tissues compared with others studies which showed only macro-CNAs. (Chen et 
al., 2004b; Garnis et al., 2004b; Baldwin et al., 2005; Snijders et al., 2005; Liu et al., 
2006; Sparano et al., 2006; Jarvinen et al., 2008). 
 
Previously, most of the studies performed genome wide screening using conventional 
CGH and PCR amplification on bacterial artificial chromosomes (BACs) clones spotted 
in the array CGH.But in these studies there was a limitation with probe used which 
started from 3-1Mb. This limitation produced high cross hybridization artifacts in the 
data analysis process and thus decreased the sensitivity and resolution that hindered the 
implementation of array CGH in research and diagnostics. Although there were few 
studies which began to use 60-mer oligonucleotide array CGH to analyse whole DNA 
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copy number profiles of OSCC, but most of these studies utilised 4x44k and 105K 
oligonucleotide array CGH. However, the probe resolutionwas not as high as the ultra 
dense 1 Million Mb oligonucleotide array CGH to detect small genomic regions with 
amplification and deletionsas in this study. Besides that, the present study was the first 
which took an effort to study the distinct subsites of OSCC (tongue and cheek SCC) by 
using the ultra dense array CGH to discover the cancer genes on these 2 subsites and the 
biological pathways involved in these 2 subsites compared to other studies.  
 
Although there were few studies that carried out genome wide analysis on OSCC as in 
the current study, none had provided signaling pathways based on the specific 
anatomical subsites of OSCC. A study on proteomic analysis of oral cancer cell line 
derived from tongue, cheek and gum SCC by Chi et al. (2009) showed that the most 
significant pathway involved in all 3 cell lines were cytoskeleton remodeling keratin 
filament pathway and type 1 IFN signaling pathway. However, they did not separate the 
pathways and proteins involved based on the specific subsite. Another study by Wang et 
al. (2009), to detect the potential pathways for the malignant transformation from 
dysplasia to OSCC also did not analyzed the pathways based on the different subsites. 
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5.1 Chromosomal aberrations (alterations) in tongue and cheek SCC using array 
CGH  
 
In the present study, chromosomal aberrations were observed in all cases. Frequent 
copy number aberrations included gains of 3q, 7p, 8q,9q, 11q, and 14q as well as losses 
of 3p, 8p, 9p and 18q which is in accordance with previous studies related to OSCC 
(Chen et al., 2004b; Garnis et al., 2004b; Baldwin et al., 2005; Snijders et al., 2005; Liu 
et al., 2006; Sparano et al., 2006; Jarvinen et al., 2008) and other solid tumors 
(Beroukhim et al., 2010). Current study demonstrated that the number of chromosomal 
aberrations in tongue SCC is higher than cheek SCC and this might be attributed to the 
more aggressive behavior of tongue in terms of invasiveness and metastasis (Hannen et 
al., 2004). This can be further supported by Hannen et al. (2004) study which 
demonstrated that metastatic of tongue SCC have higher copy number gains than non 
metastatic SCC. However, it was noticed in the current study that the deletion copy 
number of cheek SCC was higher than tongue SCC. This finding can be explained by 
the fact that those with cheek SCC in this study population were betel quid chewers. 
Earlier, studies of Lee et al. (2001b) have shown that there are high accumulations of 
mitochondrial DNA deletions in oral tissues collected fromquid chewers. This further 
explained the high incidence of cheek SCC among Southeast Asian countries where 
betel quid chewing are commonly practiced (Silverman, 2003; Pathak et al., 2009). 
 
In tumorigenesis, gene amplification is an essential step to activate the oncogenes 
(Coleman and Tsongalis, 2002). Notably, the most frequently amplified genes showed 
in tongue SCC were WISP1 (8q24.22), DENND3 (8q24.3), CCDC87 (11q13.2), 
HOXC13 (12q13.13) and CDCA4 (14q32.33) whereas for cheek SCC, the most 
frequently amplified gene was APOL1 gene (22q12.3). WISP1 (Wnt-inducted secrected 
protein 1) is one of the CCN (CTGF/Cyr61/Nov) family. They have the biological 
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properties such as regulation of cell proliferation, adhesion, apoptosis, extracellular 
matrix production, migration and growth arrest (Bringstock, 2003). WISP1 acts as β-
catenin regulated genes that are involved in tumorigenesis. They interact with DNA 
binding factors which lead to activation of uncontrolled downstream genes thatare 
normally involved in cancer (Xu et al., 2000). WISP1 has previously been reported to 
be amplified and over expressed in cholangiocarcinoma (Tanaka et al., 2003) and breast 
(Xie et al., 2001), lung (Chen et al., 2007b), colon (Pennica et al., 1998) and rectal 
cancers (Soon et al., 2003). Soon et al. (2003) in their studyshowed over expression of 
WISP1, which was found to inhibit lung metastasis and invasion.  Contrasting to these 
results was reported by Davies et al. (2005). They revealed that WISP1 expression was 
inversely linked to poor prognosis. Owing to these controversy outcomes, further 
studieson WISP1 in OSCC is needed. 
 
Amplification of DENND3 gene was also seen in lymphoblastoid cell lines from autism 
and micropapillary carcinomas (Nishimura et al., 2007; Marchi et al., 2009). The 
function of DENND3 gene remains unclear but identification of this gene in invasive 
ductal breast carcinoma warrants further study (Marchi et al., 2009). CCDC87 genes are 
encoded as a member of the coiled coil domain family, which function as dimerization 
domains for a wide variety of proteins, but its contribution to oncogenesis remains 
unclear. The gene CCDC87 was reported in invasive and non invasive melanoma cells 
(Berthier-Vergnes et al., 2011). The occurrence of this particular gene in the present 
study associated with oral cancers reflects further studies on this to understand its role 
in cancer progression. 
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HOXC13 is a homeobox-containing gene which encodes transcription factors that play 
important roles in embryogenesis and organogenesis (Yamada and Tsuchida, 2009). 
Dys-regulation of HOXC13 is well documented to be associated with oncogenesis 
(Lawrence et al., 1996; Lappin et al., 2006).  HOXC13 gene has been shown to get 
amplified at chromosome 12q13.13 in tongue SCC cell lines (Tsui and Garnis, 2010) 
and Hodgkin lymphoma (Hartmann et al., 2008).Besides that, HOXC13 gene activation 
could be resulted from chromosomal translocation, where they have fused with NUP98 
gene when associated with acute myeloid Leukemia (La Starza et al., 2003; Volgelstein 
and Kinzler, 2004; Yamada et al., 2008). However, HOXC13 genes have been 
identified as methylated gene in Methylated-CpG island recovery assay-assisted 
microarray analysison fresh frozen breast cancertissues (Tommasi et al., 2009). This 
observation was in agreement with others cancer such as colon and leukemia cell line 
(Yeang, 2010). To date, the regulatory mechanism of HOXC13 still remains unknown 
(Ansari et al., 2009), thus warranting further downstream analysis of this gene to 
confirm their roles in tumorigenesis. 
 
The current study also identified CDCA4 gene in the amplified region of 14q32.33. This 
gene encodes a protein that belongs to the E2F family of transcription factors and act as 
an important transcriptional regulator in DNA replication, cell cycle progression, DNA 
damage repair, apoptosis, cell differentiation, development and cell proliferation 
regulation through E2F/retinoblastoma protein pathway (Nevin, 1998; Hayashi et al., 
2006). CDCA4 has previously been reported to be associated with retinoblastoma 
(Hayashi et al., 2006). However, literature on association of this gene with cancer is 
lacking. 
 
81 
 
The most amplified gene in cheek SCC was mapped on chromosome 22q12.3 which 
contains APOL1. Of note, this gene encodes secreted high density lipoprotein which is 
involved in activities such as trypanosome lysis, autophagic cell death, lipid 
metabolism, cellular senescence and others vascular activities (Tzur et al., 2010). Other 
researchers have also identified the amplification and over expression of APOL1 gene 
in cervical carcinoma (Wilting et al., 2008), kidney disease (Tzur et al., 2010), prostate 
cancer (Thierry-Mieg and Thierry-Mieg, 2006), renal cell carcinoma (Kruger et al., 
2005; Camp et al., 2006). The aggressive behaviour of this gene was showed by Huang 
et al. (2003), where they indicated that APOL1 gene was associated with metagene 
predictor of lymph node metastasis in breast cancer. However, a contrasting finding was 
reported by Kim et al. (2010) who showed that APOL1 was down regulated. This 
highlighted the need for further elucidation of the role of APOL1 in OSCC.  
 
In cancer, losses of chromosomal materials most likely will harbor inactivated tumor 
suppressor genes that leads to tumorigenesis (Furukawa et al., 2006; Frohling and 
Dohner, 2008). This study identified that the most frequently deleted genes were 
TUBA3D (2q21.1), LACE1 (6q21), LRP1B (2q22.1), CNTNAP2 (7q35) and FUT2 
(19q13.33). TUBA3D is a gene that encodes microtubule constituents and is a part of 
the alpha tubulins superfamily (Khodiyar et al., 2007). This gene, together with beta 
tubulin represents the major components of microtubules that are involved in cell 
division, cell polarity, structural support and intracellular transport (Dode et al., 1997). 
The down regulation of these genes have been previously reported in Ewing Sarcoma 
(Mukhopadhyay et al., 2010), while Ben-Chetrit et al. (2005) reported that the loss of 
TUBA3D will suppress the anti inflammatory effects in cancer by decreasing the 
neutrophil migration towards the inflammatory site. 
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LACE1 has been reported to be down regulated in B-cell lymphoma cell lines (Inomata 
et al., 2009) and they are also reported to be deleted in early stages of lung 
adenocarcinoma (Mikse et al., 2010). Although LACE1 has been implicated as a tumor 
suppressor gene, its genetic inactivation has not been observed in any cancer. Thus, 
further functional evaluation of this gene is worth for investigation. The deletion of 
LRP1B gene as found in the present study is in concordance with previous reports. In 
early studies this gene was frequently reported to be silenced and under expressed in 
oral cancer (Cengiz et al., 2007), esophageal SCC (Sonada et al., 2004), urothelial 
cancer (Langbein et al., 2002) and B-cell lymphoma (Rahmatpanah et al., 2006). 
Initially, LRP1B was termed as LRP-DIT (deleted in Tumors) and was consideredas a 
member of the LDL receptor family (Dietrich et al., 2010). As the name implies, this 
gene is suggested as the potential tumor suppressor gene happening due to the specific 
deletion through genetic and epigenetic mechanism on CpG Island (Marschang et al., 
2004; Dietrich et al., 2010). Both studies of Liu et al. (2000a) and (2000b) showed that 
loss and inactivation of LRP1B plays an important role in enhancing tumor invasion and 
metastasis through regulation of extracellular proteolysis and cell motility in late stages 
of lung cancer progression. Although loss of LRP1B have been reported in oral cancer 
(Cengiz et al., 2007), the mechanism of this gene remains unclear, further downstream 
analysis should be performed to clarify its role in oral carcinogenesis. 
 
Traditionally, CNTNAP2 gene has been found to be associated with neurological 
disorders as this gene is a member of  neurexins superfamily, which is a group of 
transmembrane protein that assist cell-cell interactions in nervous system (Baumgarther 
et al., 1996). Deletion of this gene could lead to unwanted movement due to the 
disturbance of K
+ 
channel distribution in the nervous system (Verkerk et al., 2003). 
Previous studies reported the association of this gene with focal epilepsy (Friwdman et 
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al., 2008), schizophrenia (Friwdman et al., 2008), autism (Alarcon et al., 2008), speech 
and language disorders (Petrin et al., 2010) and Gilles de la Tourette syndrome 
(Verkerk et al., 2003). Interestingly, this gene was also found to be deleted in the 
present study. Moreover, this gene was also associated with other types of cancer such 
as pancreatic adenocarcinoma (Omura et al., 2008), neuroblastoma (Stalling et al., 
2006), myeloid leukemia cell line (McAvoy et al., 2007), breast (McAvoy et al., 2007), 
ovarian (McAvoy et al., 2007), endometrial (McAvoy et al., 2007) and brain cancers 
(McAvoy et al., 2007). The nature of this gene which was found at the common fragile 
site explains its nature as a TSG (Smith et al., 2005). However, this suggestion is in 
disagreement with Chen et al. (2008) where they showed that CNTNAP2 gene was over 
expressed in oral squamous cell carcinoma. This contradiction might be due Chen et al. 
(2008) take an effort to compare the gene expression of OSCC with normal control 
which derived from normal oral tissue and dysplastic oral lesion, and this comparison 
data hence will be different with our study. This suggested that CNTNAP2 expression is 
copy number independent and could be another primary driving forcebehind this gene 
deletion in chromosome 7q35. 
 
FUT2 gene encodes an α-(1, 2) fucosyltransferase that controls the expression of the 
ABH antigens in saliva and mucosal tissues (Serpa et al., 2004). The current knowledge 
suggests that homozygous nonsense mutation of this gene is strongly associated with 
resistance to novovirus infections (Thorven et al., 2005). The deletion of FUT2 gene 
found in the present study was in agreement with the study of Massion et al. (2008), 
which performed a genome wide screening on frozen non small cell lung cancer tissues. 
However, the findings from both these studiesare in contrast to the study conducted by 
Madjd et al. (2005), where the expression of FUT2 gene was inversely proportional to 
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survival in lymph node negative breast carcinomas. The controversy surrounding the 
involvement of FUT2 gene in tumorigenesis suggests further investigation of this gene.  
 
5.2 Significant pathways involved in tongue and cheek SCC using pathway analysis 
software. 
 
There is currently a limited understanding of the biological pathways involved between 
tongue and cheek SCC. The discovery of potential markers has represented a substantial 
challenge particularly for markers that are applicable to subsite of oral cancer. The 
interest in the current project was to identify the genes that interact together during oral 
carcinogenesis. Hence, the pathway analysis was carried out to associate the genes with 
various copy number alterations in oral cancer. Pathway analysis was performed to 
determine the biological pathways of the amplified and deleted genes to further 
understand the mechanism of oral carcinogenesis. Thirty-five (19.7%) out of 178 
amplified genes were found to be enriched in tongue SCC analysis. Pathway analysis of 
these 35 genes identified four significant pathways using Metacore's Genego pathway 
tool. Some of the important top pathways generated by Genego include; cell adhesion 
extracellular matrix (ECM) remodeling, proteolysis role of Parkin in the Ubiquitin-
Proteasomal, development of beta-adrenergic receptors signaling via cAMP and cell 
adhesion cadherin mediated cell adhesion pathway. 
 
Identified significant pathways in tongue SCC is as illustrated in table 4.6 where the 
most significant pathway was related to cell adhesion ECM remodeling. Altogether 11 
key downstream regulators were found in this pathway (EFGR, ITGB1, LAMA3, 
LAMB3, MMP1, MMP10, MMP12, MMP13, MMP3, MMP7 and MMP9) were 
identified. Identification of this pathway has been previously reported by Luna et al. 
(2009) where they suggested that the alteration of ECM in cell adhesion, ECM-
remodeling pathway was highly induced by chronic oxidative stress. Besides that, other 
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researchers has shown that this pathway was involved in chronic pancreatitis, breast 
cancer and ovarian cancer (Pitteri et al., 2009; Reding et al., 2009; Bessarabova et al., 
2010). Of note, ECM remodeling is important in the development of malignancies due 
to proteolysis of the ECM, which allow tumor cells to invade and penetrate through 
basement membrane barrier in the process of tumor invasion and metastasis (Stetler-
Stevenson and Yu, 2001). MMPs are known as a "protease in invasion" in this pathway. 
They degrade the various components of the ECM and favor metastases (Stetler-
Stevenson and Yu, 2001). Proteolysis of the ECM is a crucial initial step in the 
mechanism of tumor cell invasion. In order for cells to invade and spread they must be 
able to first penetrate into connective tissue barriers such as the basement membrane, 
provisional matrix or interstitial stroma that surround tumors and existing blood vessels. 
The mechanism of this pathway in tumorigenesis can be explained by the release of 
active HB-EGF which is cleaved by MMP7 activated its receptors. The gene, EGFR 
were found to induce cell proliferation, cell survival and tissue remodeling (Rehault et 
al., 2001; Yu et al., 2002). The cell adhesion movement mainly caused by the binding 
of ITGB1 to collagen IV during ECM remodeling pathway favors cell invasion and 
metastasis (Li et al., 2006). The involvement of this pathway in tongue SCC further 
explains its aggressive behavior in oral cancer.  
 
Dys-regulation of proteolysis role of Parkin in the ubiquitin-proteosomal pathway has 
been previously reported in Bovine Leukemia virus infection (Li et al., 2009) and 
arsenic induced bladder cancer (Sen et al., 2007). The role of Parkin in these pathway 
was regulated by E3-ubiquitin protein that ubiquitinates and degrade the tubulin alpha 
and tubulin beta (Ren et al., 2003). Basically, the deletion of Parkin increased the level 
of Parkin associated endothelin receptors like PAELR, leading to the dopaminergic 
neuron degeneration and apoptosis inhibition (Imai et al., 2001). This is one of the 
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hallmarks in tumorigenesis as described by Hanahan and Weinberg (2000). This is 
further supported by an example of numb gene which is regulated by E3-ubiquitin 
where the lost expression of this gene in breast cancer leads to an uncontrolled cell 
proliferation (Pece et al., 2004). This implied that PARK2A and TUBA3D might act as 
a negative regulator for this pathway in oral cancer through ubiquitination and 
proteasomal degradation where loss of these genes can increase cell proliferation. Our 
findings may further contribute to the understanding of key biologic functions and 
pathways of certain ubiquitin and proteasomal degradation protein genes that are 
associated with OSCC. However, further investigations into ubiquitin genes arerelevant 
in oral carcinogenesis. 
 
Amplification of INHBA gene was detected using array CGH in the present study and 
has been recognized as one of the member in the pathway of cytoskeleton remodelling 
(Role of Activin A). Activin A which is also known as INHBA is a member of the 
transforming growth factor beta (TGF-ß) (Vale et al., 2006). In this pathway, INHBA 
plays its role by binding to either activin A or B type II receptors (ActRIIA or ActRIIB), 
which are membrane-spanning serine/ threonine kinase receptors to form a complex 
(Vale et al., 2006). These complexes commence a signaling cascade which involves 
specific transcription factors such as SMAD2, SMAD3 and SMAD4 (Mathews, 1994). 
The binding of SMAD4 to SMAD2 and SMAD3 forms a complex and is translocated 
into the nuclease to promote cell differentiation and cell proliferation (Zhang et al., 
2005). Furthermore, INHBA also activates RhoA which leads to the formation of 
transcription of independent actin stress fibres which are accounted for actin 
cytoskeleton reorganization and cell migration (Zhang et al., 2005). This pathway has 
been reported by Nambiar et al. (2010) in a study on colon cancer metastasis. The 
involvement of INHBA in tumorigenesis have been widely studied in different type of 
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cancers such as prostate cancer, lung adenocarcinoma, endometrial adenocarcinoma, 
esophageal SCC, ovarian cancer, cervical carcinomas and colon carcinomas (Petraglia 
et al., 1998; van Schaik et al., 2000; Wildi et al., 2001; Simone et al., 2002; Woodruff, 
2002; Yoshinaga et al., 2007; Seder et al., 2009). These findings suggested that this 
gene might be a potential therapeutic target for oral cancer. 
 
Another pathogenic pathway identified in the present study was the ERBB-family 
signalling pathway and the gene involved in this process was NRG1 gene. The binding 
of NRG1 which is an extracellular growth factor ligands to ERBB3 which causes the 
activation of intracellular signaling pathways that regulates diverse biologic responses 
including proliferation, differentiation, cell motility, and survival in cancer (Sweeney 
and Carraway, 2000; Marmor et al., 2004; Revillion et al., 2008). These finding was 
supported by a study in ovarian cancer cell lines where activation of NRG1/ErbB3 
autocrine loops increases cell proliferation (Sheng et al., 2010). Furthermore, 
expressions of ErbB-3 and ErbB-4 have been previously reported in OSCC, childhood 
medulloblastoma and breast cancer (Xia et al., 1999; Gilbertson et al., 1997; Yarden, 
2001). 
 
The present study now report for the first time that CTNNA3 and PTPRM genes, which 
are associated with cadherin mediated cell adhesion pathway are deleted in OSCC. This 
finding showed that besides E-cadherin, others members of the junctional complex also 
accounts for the impaired cell to cell adhesion. Previously, this pathway have been 
reported in colon cancer (Nambiar et al., 2010) and the deletion of CTNNA3 and 
PTPRM have been identified in lung squamous cell carcinoma, endometrial carcinoma 
and bladder cancer (Kim et al., 2002; McDoniels-Silvers et al., 2002; Meehan et al., 
2007). Early study showed that the loss of CTNNA3 has been positively associated with 
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tumor invasion and metastasis (Shiozaki et al., 1996). This pathway suggested that 
CTNNA3 which is one of the catenin members will interact with other catenins to allow 
the association of cadherins to form catenin/cadherin complex (Goodwin and Yap, 
2004). The connections of this complex to actin cytoskeleton via α-catenin together with 
the involvement of PTPRM dephosphorylated induce a stable intercellular cell to cell 
adhesion (Brady-Kalnay et al., 1998). The dys-regulation of this pathway explained the 
detachment of cancer cells for invasion via the loss of tight adherens junction (cell to 
cell adhesion), which is resulted from the defect in binding of the catenin/cadherin 
complex with actin microfilament network of the cellular cytoskeleton (Frixen et al., 
1991; Thiery, 2002). This supports the suspected behaviour of the loco-regional failure 
in cheek SCC. 
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Study Limitation: 
Even though a higher resolution array CGH was employed in this study, it still suffers 
from several limitations despite being a powerful technology to detect genomic 
abnormalities in terms of copy number variation. Another limitation found in the 
present study was regarding the small sample size which consisted of only 20 OSCC 
samples. In fact the sample size considerably influenced the biological conclusion 
derived using array CGH. The frequency of copy number variation in 20 OSCC patients 
will be differed with hierarchical clustering and may affect the overall estimation of 
frequency of variation. Furthermore, this study did not analyze the copy number 
aberrations parallel to the gene expression level. This can be achieved by integrated the 
copy number aberrations with gene expression data that derived from a public database 
to identify specific target genes that altered the gene dosage caused by the chromosomal 
aberrations. Apart from that, one of the major difficulty using array CGH is the 
involvement of high cost, which could not be afforded by the public and thus making it 
a difficult tool for diagnostic. 
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6.0 Conclusion and recommendations 
The primary objective of the current research was to determine the chromosomal 
aberrations in tongue and cheek SCC using array CGH technology. The results from the 
present study to determine chromosomal aberrations in tongue and cheek SCC using 
array CGH technology has revealed that there was difference in set of chromosomal 
aberrations from both subsites. 
 
The second objective was to identify the genes involved in tongue and cheek SCC using 
array CGH technology. For this objective, this study has managed to compile a list of 
amplified and deleted genes detected from tongue and cheek SCC using array CGH. 
 
The final objective was to determine the significant pathways involved in tongue and 
cheek SCC using pathway analysis software. The present study has showed that there 
were different biological pathways involved in tongue and cheek SCC. The results 
revealed that, the most significant pathway involved in tongue SCC was cell adhesion 
ECM remodeling pathway. This finding has further strengthened the explanation for the 
reason behind the more aggressive behaviors in tongue SCC than others subsites of oral 
cancer. Although the feature of the Metacore software is often debatable, however, it is 
recommended that in order to validate the said pathways, more cellular biology 
experiments have to be conducted. 
 
Overall, this study has showed there are differences in chromosomal aberrations, gene 
and its pathways tongue and cheek SCC. The observations from the present research has 
opened up a stepping stone for the future researchers to explore the chromosomal 
aberrations, genes, their interactive pathways and role on oral carcinogenesis. 
Nevertheless, this study has managed to utilize high resolution array CGH to perform 
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genome wide copy number profiling to identify copy number alterations that are 
associated with oral cancer subtype in frozen tumor tissues. This has provided useful 
information on the molecular biology of genetic alterations in oral carcinogenesis which 
could be considered in the management of oral cancer. Integrative analyses of different 
data types and advanced molecular profiling have enabled us to relate these alterations 
to the activities of oncogenic pathways and subsequently this could be made useful for 
the identification of suitable therapeutic opportunities.  
 
Recommendation: 
In the future, the findings from the high-resolution array CGH can be validated using 
larger number of samples on customize lower resolution array CGH which comprising 
of the targeted CNAs that are specific for oral cancer based on the ultra dense array 
CGH platform. This is proposed due to fact that by customizing the array CGH with 
targeted CNAs that specific for oral cancer, this would reduce the costing for the array 
CGH. Through this attempt large numbers of samples are could be involved and 
validate using the customized array CGH to validate the specific CNAs for oral cancer. 
Moreover, the significant association with socio-demographic profile or 
clinicopathological parameters could be also attempted. It could also improve the 
probability of detecting recurrent segmental copy number alteration and other 
mechanisms such as epigenetic changes and mutations at the sequence level, which can 
contribute to specific genes deregulation. The present study has identified the genes that 
are residing in recurrent chromosomal regions of tongue and cheek SCC. Therefore, in 
order to obtain a more complete picture of cancer, future efforts can be made to 
combine the array CGH approaches with transcriptomic and proteomic technologies. 
This can be done by integrating the copy number data with public expression dataset to 
identify the potential driver genes. 
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Oral cancer has been documented as a heterogenous tumor group, due to their 
occurrence at various sites within the oral cavity and their different biological 
behaviours. In view of this, the genomic alterations of others subsites within the oral 
cavity such as gum, floor of mouth and hard palate is further recommended for future 
study and thus it would have been possible to determine their genetic alterations of the 
different subsites. 
 
Although array CGH has been offered as the first tier diagnostic tool, the economics is 
not favourable to public at the moment. As this study have detected potential unique 
genes for tongue and cheek SCC out of 24,500 genes in the human genome sequence 
project, the implicated genes should be further studied. Moreover, their role in oral 
carcinogenesis should be also uncovered in detail. This could be carried out using the 
low costing quantitative PCR technique to determine their gene expression level. These 
results will certainly add to the present knowledge of oral carcinogenesis and might be 
useful for future application in the prognosis and therapy of OSCC. 
 
 
 
 
 
 
 
 
 
 
 
